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Abstract 
 
Background: We are at the beginning of a new era where regenerative medicine is 
really starting to take hold. An appreciation of adult stem cells and their role in tissue 
maintenance have heralded novel insight into endometrial remodelling. The idea that 
human endometrium could be a plentiful source of adult stem/progenitor cells 
(ASPCs) has captured the imagination of many stem cell biologists. Not only that, 
they are also hypothesised to be involved in endometrial proliferative diseases, such 
as endometriosis. However, work remains preliminary and is stunted by a lack of 
specific endometrial stem cell markers. Recently, stage specific embryonic antigen -1 
(SSEA-1) was proposed as a candidate epithelial ASPC marker in adult 
endometrium. In order to validate this, stem cell assays are required. These assays 
include measurements of clonogenicity, prolonged self-renewal and differentiation 
potential.  
 
Aim: To assess the differentiation potential of SSEA-1+ cells in vitro. 
 
Methods: All endometrial culture samples were collected from pre-menopausal 
women undergoing surgery for benign disease at Liverpool Women’s Hospital 
(LWH). Epithelial cells were cultured in 3D MatrigelTM to produce gland-like 
structures. Gland-like structures were characterised via immuno-histochemistry, to 
validate their resemblance to glands in endometrial tissue in vivo. To assess multi-
potency, magnetic cell sorted (MACS) SSEA-1 enriched and depleted cell fractions 
were cultured in adipogenic and osteogenic inducing media. In order to assess 
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pluripotency, SSEA-1 enriched and depleted fractions were cultured in neurogenic 
media.  
 
Results: SSEA-1 enriched cell fractions had a greater propensity to produce gland-
like structures in 3D culture than SSEA-1 depleted cell fractions. Gland-like 
structures best resembled glands in post-menopausal (PM) endometrium. Non-gland 
like structures also formed in 3D culture from endometriosis samples, which stained 
exclusively and intensely for CK5/6. SSEA-1 enriched and depleted fractions were 
unable to differentiate into other cell types of mesodermal lineage. However, both 
enriched and depleted fractions were able to produce ectodermal derived neural-like 
PGP9.5 positive cells. 
 
Discussion: This work confirms SSEA-1 is a reliable epithelial ASPC marker in 
adult endometrium. SSEA-1+ cells possess an increased ability to produce gland-like 
structures, reminiscent of in vivo endometrial glands. This therefore confirms 
unipotency. The presence of CK5/6 in non-gland-like structures from endometriosis 
samples suggests a potential role in endometriosis aetiology, and warrants further 
work.  SSEA-1 enriched and depleted cells were unable to undergo multi-lineage 
differentiation, but were capable of producing neural-like cells. As both cell 
populations were unable to demonstrate multipotency, it unlikely SSEA-1 
enriched/depleted cells are pluripotent. More likely, a neural progenitor may exist in 
adult endometrium, one that has been included in both cell populations.  Given the 
close proximity of endometrial glands to the placenta, the commitment of epithelial 
stem cells could be an ancillary mechanism to prevent maternal microchimersim in 
offspring, which is associated with a number of pathologies.  
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Chapter One: INTRODUCTION 
The organised regenerative ability of human endometrium is unmatched by any other 
organ. Under the influence of ovarian hormones, the uterine lining undergoes a 
monthly cycle of proliferation, differentiation and shedding. Conclusive work has 
highlighted mechanisms underpinning endometrial shedding, yet there persists a void 
when trying to understand endometrial re-growth. A new era of regenerative 
medicine, and an appreciation of stem cells have heralded novel insight into 
endometrial expansion; it is likely stem cells are implicated in endometrial 
proliferation and proliferative disorders. In order to evaluate the possibility of 
endometrial stem cells in health and disease, a thorough literature review on the 
subject will be discussed. 
 
 
1.1: Endometrial Structure and Function 
1.1.1: Human uterus 
The human uterus is a hollow muscular pear shaped organ, approximately 7.5cm in 
length. It serves to act as a conduit for the migrating sperm, and houses the 
development of the embryo and foetus. It is arguably the most plastic organ, in terms 
of tissue remodelling.1  
 
The uterus consists of the fundus superiorly, the corpus, and the cervix inferiorly. It 
has three openings; the two fallopian tubes and the external os, which connects the 
uterus with the vagina. Structurally, the uterus is covered with peritoneum and 
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contains a thick muscular layer (myometrium), made up of a criss-cross of 
involuntary fibres mixed with fibro-elastic connective tissue (Figure 1.1). The inner 
lining of the uterus is termed the endometrium. Human endometrium serves three 
main functions; to maintain the patency of the uterus by preventing adhesions from 
surrounding myometrium; to provide an optimum environment for potential 
implantation of a blastocyst; and should implantation occur, it forms the decidua in 
pregnancy.    
 
 
 
 
 
 
 
 
 
 
 
1.1.2: Human endometrial composition 
Histologically, endometrium differs on account of its location within the uterus. 
Endometrium is present in the fallopian tubes and uterine corpus. The cervical canal 
does not contain endometrium; the endocervix is made up of tall columnar cells, 
which form a series of complicated branching glands. It is these glands that secrete 
the ‘cervical plug’, an alkaline mucus, which forms a protective barrier.3 The 
endometrium of the fallopian tubes contains columnar ciliated cells. The purpose of 
 
Figure 1.1: Coronal cross-section of human uterus and vagina. Schematic diagram 
demonstrating anatomical composition of the human female reproductive organs and 
divisions of the human uterus, adapted from Drake et al.2 
Cervix 
Corpus Fallopian 
Tube 
Vagina 
Opening of Fallopian Tube 
Fundus 
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this is to aid in transportation of the zygote to the corpus. The endometrium of the 
corpus is made up of a single layer of ciliated epithelial cells, which rest on a bed of 
connective tissue. The connective tissue is formed by a pool of stromal cells, which 
harbour a rich blood supply in the form of spiral arterioles, along with leucocytes and 
nerve fibres. Simple tubular epithelial glands dip down from the luminal edge to the 
base of the stroma. It is the endometrium of the uterine corpus that undergoes 
extensive changes during the menstrual cycle and shall be discussed in detail 
throughout this chapter.  
 
Endometrium of the uterine corpus varies in thickness, ranging from 1mm during 
menstruation up to 10mm in the secretory phase.4 It can be divided into two main 
layers; the basalis/basal layer and the functionalis/functional layer (Figure 1.2). The 
basal layer is adjacent to the myometrium and remains constant throughout a 
woman’s life. It comprises dense stroma, large blood vessels and glandular bases. It 
is the basal layer that generates the transient functionalis each month. The 
functionalis is adjacent to the uterine cavity, and undergoes partial/complete 
disintegration and regeneration in response to oestrogen and progesterone. The 
purpose of remodelling is to provide an optimum environment conductive to 
implantation of the conceptus, but only when appropriate.5,6  
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1.1.2i: Epithelia 
Epithelia are continuous sheets of tightly linked cells that constitute mucosal surfaces 
and linings. They form the parenchyma of most tissues. Epithelia can be simple, 
stratified or ‘pseudo-stratified’. They possess an elegant intrinsic scaffold that 
maintains cell polarity, provides anchorage to the basement membrane, and 
facilitates important inter-cellular communications. In culture, epithelia aggregate in 
clusters and are typically polygonal in shape. The presence of cytokeratin (CK) is 
definitive of epithelia. They can be either luminal; lining cavities, or glandular; 
forming endocrine or exocrine glands. Luminal epithelia have a particularly 
important function in the endometrium; apposing and adhering to the implanting 
blastocyst. Glandular epithelia sustain the trophoblast during the first-trimester, as 
maternal circulation to the human placenta is not established until 10-12 weeks.7 
Functionalis 
Basalis 
Luminal 
Epithelia 
Stroma 
Glandular 
Epithelia 
Blood 
Vessel 
Myometrium 
Figure 1.2: Micrograph of full thickness human endometrium. Haematoxylin and 
Eosin staining of a full thickness section of human endometrium. 
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They secrete a cocktail of growth factors including alpha tocopherol transfer protein 
(αTTP), transforming growth factor (TGF-β3) and leukaemia inhibiting factor (LIF).8  
 
1.1.2ii: Stroma 
Endometrial mesenchyme harbours a collection of stromal cells, blood vessels, nerve 
fibres and leukocytes. Stroma are undifferentiated cells that have the ability to 
migrate in tissue. As epithelial cells are avascular, stromal cells play a supportive 
role; providing the right environment to permit the epithelial cells to function. 
Stroma form the extra-cellular matrix (ECM), a complex pool consisting of 
collagens, fibronectin, glucose and growth factors. Most endometrial stromal cells 
resemble undifferentiated fibroblasts, which under the influence of progesterone 
engorge to become ‘pre-decidua’ in the late secretory phase and decidua in 
pregnancy.9 More recently, work has shown the stromal cells are responsible for the 
cascade of reactions leading to endometrial breakdown.10  
 
1.1.2iii: Leucocytes  
Leucocytes are heavily influential in the remodelling of endometrium. They account 
for 7% of the stromal fraction in the proliferative phase, and this greatly increases to 
40% at the time of menstruation.9,11 Resident lympho-myeloid cells consist of T 
lymphocytes, macrophages and uterine natural killer cells (uNK). T lymphocytes are 
located in lymphoid aggregates at the base of glands or intra-epithelialy. 
Macrophages and uNK both increase during the mid to late-secretory phase and are 
speculated to have a role in angiogenesis.12  
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1.1.2iv: Endothelia 
The uterine and ovarian arteries provide the blood supply to the endometrium. Radial 
arteries form in the myometrium, crossing the endometrial border to become 
anastomosing basal arteries in the basalis. These branch off to become terminal spiral 
arteries in the functionalis and form a sub-epithelial plexus under the luminal 
epithelia. Endometrial endothelia are not immune to the cyclical changes of the 
menstrual cycle. The process of endothelial regeneration is complex, and will only be 
discussed very briefly here. Angiogenesis dominates vessel formation; vessel 
elongation is a major mechanism in the late proliferative phase, followed by a stage 
of remodelling via vessel intussusception.13,14  
 
1.1.2v: Nerve fibres 
Neurons are specialised cells that are electrically excitable. Work to establish the 
presence of neural fibres in normal human endometrium is lacking. One study 
demonstrated the presence of neural fibres in the basal third of human endometrium 
but these were lost in the functional layer.15 Presumably, neurons within the 
endometrium do not undergo cyclical regeneration. 
 
1.1.3: The menstrual cycle 
The menstrual cycle is present in humans, primates and the elephant shrew.16 The 
reason behind menstruation is unclear but there is a link between mammals which 
menstruate and those who exhibit haemo-chorial placentation (maternal blood comes 
into direct contact with the foetal chorion).17 The reason for menstruation is most 
likely to improve nutrition for the potential blastocyte. The blood supply to the 
placenta does not arise until 12 weeks gestation; until this period the decidua is 
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responsible for nutritional support.7 During the cycle, stroma undergo priming to 
improve nutritional status in the form of ‘decidualisation’. This is a non-reversible 
transformation and therefore if implantation does not occur, these cells must be 
discarded and a replacement formed.18 
 
The menstrual cycle is described as 28 days in length. It comprises the uterine and 
ovarian cycle: the two run concomitantly, and the ovarian cycle plays a critical role 
in regulating its uterine counterpart. The menstrual cycle is divided into three phases; 
menstrual (day 1-4), proliferative/follicular (day 5-14) and secretory/luteal (day 15-
28). The cycle relies on negative feedback of oestrogen and progesterone on 
gonadotrophin releasing hormone (GnRH) and the pituitary hormones; follicular 
stimulating hormone (FSH) and luteinizing hormone (LH). 
 
 
 
 
 
 
 
 
Day 14                 Secretory  Proliferative  Menstrual 
Oestrogen 
Progesterone 
LH 
FSH 
Figure 1.3: Hormonal changes in the menstrual cycle. The cycle is divided into 
three phases. Oestrogen levels gradually increase during the proliferative phase, 
resulting in an LH spike at day 14. Once ovulation has occurred, progesterone 
levels increase in the secretory phase. If fertilisation does not take place, the cycle 
is repeated and menstruation ensues.   
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1.1.3i: The ovarian cycle 
Human ovaries are the female gonads, existing in pairs and attached to the uterus via 
the ovarian ligaments. They serve to produce ova, a process known as oogenesis, and 
secrete the female sex steroids oestrogen and progesterone. Oogenesis is a long and 
intermittent process. Primitive precursors (oogonia) initially undergo mitosis and 
maturation, during the third trimester of foetal life, to become primary oocytes. At 
birth, it is estimated a female possesses 2 x 106 primary oocytes.19 The primary 
oocytes (diploid cells) begin the first stage of meiosis shortly after parturition. 
However, development is arrested in prophase I until puberty. At this point, growth 
and development is independent of GnRH.20 After puberty, a primary oocyte 
completes meiosis I prior to ovulation. This produces a secondary oocyte and a small 
polar body. Only 400 primary oocytes reach this stage; the rest undergo atresia.19 
Meiosis II only is completed if fertilisation occurs, resulting in an ovum and a second 
polar body.  
 
Follicles are the basic units of the ovary and house the developing oocyte. These also 
undergo a maturation process similar to the oocyte. Primoridal follicles form in utero 
and house the oogonia. From birth onwards, primordial follicles mature to become 
primary follicles, producing the mucopolysaccharide zona pellucida, around the 
oocyte, and developing granulosa and theca cells. The ovarian cycle has two phases: 
follicular and luteal. 
 
Follicular phase 
At the beginning of the cycle, oestrogen and progesterone levels are low. Due to 
negative feedback, GnRH is released from the hypothalamus causing FSH and LH to 
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be released from the anterior pituitary.21 As the name would suggest, FSH 
encourages follicular growth; theca cells increase in number and differentiate to 
become the theca interna and externa of the ovum. Theca cells also recruit androgens 
and convert into oestrogen. Granulosa cells too increase in number and secrete a 
serous fluid, causing the follicle to engorge so that it becomes grossly visible on the 
ovarian surface. The increase in intra-follicular pressure makes it prone to rupture. 
Oestrogen levels continue to rise and would normally produce a negative feedback 
effect. However, when oestrogen levels rise above to a significant level, a positive 
feedback effect is observed and produces an LH surge, ultimately leading to 
ovulation.21 
 
Luteal phase 
During ovulation the primary follicle ruptures and is released from the ovary. It 
produces two products; the secondary oocyte (surrounded by the zona pellucida and 
granulosa) and follicular remnants. Under the influence of LH, follicular remnants 
develop into the corpus luteum, which is the source of progesterone. The corpus 
luteum has a fixed life span of 12-14 days if implantation does not occur and 
thereafter it undergoes apoptosis; progesterone levels decrease and the cycle is 
repeated unless pregnancy is established.22 
 
1.1.3ii: The uterine cycle 
The uterine cycle describes the morphological changes and remodelling of the 
endometrium. As mentioned earlier, it runs concomitantly with the ovarian cycle, 
and is controlled largely by ovarian hormones. The follicular phase of the ovarian 
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cycle correlates with the menstrual and proliferative phase of the uterine cycle. 
Similarly the luteal phase is representative of the secretory stage.  
 
Menstrual phase 
Day 1 of the cycle is considered to be the first day of menstruation and is the result 
of progesterone withdrawal. There has been considerable controversy regarding the 
believed mechanism underpinning menstruation. Markee et al. initially proposed 
hypoxia was the driving force, after a series of experiments transplanting endometria 
into the eyes of rhesus monkeys.23 However, there has since been a shift in thinking. 
Hisaw and Hisaw in 1961 demonstrated menstruation occurred even in the presence 
of atrophy.24 In addition, hypoxia inducing transcription factors-1α (HIF-1α) and 
HIF-2α, are barely detectable within the endometrium in the peri-menstrual phase.25 
 
The most accepted dogma proposes that matrix metalloproteinases (MMPs) are key 
players in initial focal breakdown.10,26 MMPs are secreted in latent forms by 
endometrial stromal cells, and are activated either by other MMPs (mainly MMP-3 
and MMP-9) or products of leucocytes. Studies have demonstrated MMP inhibitors 
can stop the breakdown of endometrial explants in culture.27 Natural tissue MMP 
inhibitors (TIMPs) have also been found within the endometrium, indicating there is 
a delicate interplay between tissue breakdown and maintenance.28 
 
There is also evidence to suggest that menstruation is the consequence of an immune 
reaction. Kelly et al. demonstrated that progesterone negatively regulates IL-8 
expression in endometrium, resulting in leukocyte migration.29 Leucocytes produce 
enzymes, namely elastase and tryptase, converting latent MMPs into their active 
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counterpart. Once this takes place, a cascade of MMP reactions occurs. The resulting 
fragmentation leads to loss of blood vessel integrity and hypoxia shortly ensues, 
causing rapid degeneration of the functional layer and blood loss.9 Ancillary 
mechanisms exist to restrict loss; Endothelin 1 (ET-1) has been shown to be 
important at controlling blood loss, whereas TIMPs are activated to restrict 
endometrial loss.30 Scanning electron microscopy has revealed that small lesions are 
apparent as early as the late secretory phase, supporting that rapid endometrial 
dissolution is a consequence of initial focal breakdown.31 
 
Apoptotic bodies are also found within the endometrium, interestingly most are 
found within glandular epithelia and very low levels are observed in stroma. Reports 
have shown Bcl-2-associated X protein (BAX), a pro-apoptotic protein initiating 
mitochondrial permeablization, to be poorly expressed in proliferative epithelia but 
high in secretory epithelia.32 The reverse pattern is observed with Bcl-2, an anti-
apoptotic marker.32,33 Similarly, ‘death receptors’ Fas and Fas/L are present 
throughout the cycle but inactive. It is only during the late secretory phase, under the 
influence of MMPs, they become active via incorporation into the cellular 
membrane.33 Therefore, it would seem menstruation is an interplay between an 
inflammatory response, hypoxia and apoptosis. 
 
Proliferative phase 
The proliferative phase follows menses and involves priming of the endometrium as 
a response to oestrogen. The length of this phase can vary from 9-23 days.34 
Morphologically, the endometrium becomes thicker due to acquisition of the 
functionalis, increasing in thickness to 4mm.4 Glands begin as fairly undifferentiated, 
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short and straight, with a circular cross-section, but by the end of the phase 
functional glands are long and tortuous. Differences of epithelia are also observed on 
a cellular level. Glandular epithelia gradually increase in length to become tall and 
columnar. Pseudo-stratification increases, reaching a maximum at day 10 in a 28 day 
cycle.35 Although increased mitotic activity, stroma undergo very little 
differentiation during this phase. Interestingly, scanning microscopy has revealed a 
shared origin for re-epithelialisation. Outgrowth from exposed basal glands runs 
alongside ingrowth from the peripheral surface membrane; stroma in the functionalis 
is only formed once the endometrium has been completely re-epithelialised.36  
 
Secretory phase 
After the re-growth of the functionalis, the influence of progesterone brings about 
differentiation. The secretory phase lasts 14 days, allowing for little variation. The 
stage aims to create an optimum environment for embryo implantation. However, 
early and late secretory endometria are still non-responsive to the conceptus; there is 
only a very small timeframe in which the endometrium is receptive. In 1973, 
Psychoyos coined the term ‘Window of Implantation’ (WOI) to describe days 20-24 
(in a 28 day cycle).37 This can be regarded as the most differentiated form the 
endometrium takes; the only time when it is receptive to the blastocyst. This is 
believed to be a survival mechanism and only permits implantation of the blastocyst 
at the correct stage of development.5,6 
 
It is now that glandular activity is at its highest. The collection of secretions is 
termed the histotroph and is the subject of much research. Glandular epithelia lose 
their pseudo-stratified appearance; sub-nuclear vacuoles push the nuclei to the apical 
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surface.4 Gland luminal diameter also reaches its maximum, causing glands to 
occupy nearly a quarter of the endometrium.4 
 
One key feature of luminal epithelia is its ability to accept/reject a blastocyst – it is 
during the WOI that this characteristic now comes into play. By day 20 (of a 28 day 
cycle), flattened ‘droplet like’ projections appear on the luminal surface.38 These 
deposits, called pinopodes/uterodomes, are believed to be ‘landing platforms’ for the 
potential blastocyst and disappear within 4 days of formation.39 Other biochemical 
changes have been documented; Muc-1, a mucin thought to cause steric hindrance 
between blastocyst and luminal apical surfaces is locally down-regulated at 
implantation sites in humans.40  
 
During the last week of the cycle, glandular secretions cease and glands take on a 
characteristic serrated appearance. At this point, it is the stromal population that 
takes centre stage; stromal phenotype dramatically changes from undifferentiated 
fibroblast to something that best resembles epithelia. Under the influence of 
progesterone, stroma engorge, accumulate glycogen and become secretory.4 If 
implantation occurs, this phenotype continues into pregnancy. 
 
1.1.4: Hormone receptors 
Expression of the hormone receptors also alters throughout the course of the cycle 
and will only be discussed briefly here. As expected, oestrogen receptor (ER) is 
greater expressed in the proliferative phase. Two forms of oestrogen receptor exist; 
ER-α and ER-β. ER-α is present in both stroma and epithelia of the functionalis. ER-
β is not detected in the stroma but only this form is present in vascular endothelia.9 
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Knockout studies in mice would suggest ER-α is crucial at preserving fertility 
whereas ER-β is dispensable.41 Similarly, two forms of PR also co-exist, PR-A and 
PR-B.  
 
1.1.5: Endometrial morphogenesis 
The female reproductive organs are formed from the mesonephric (Wolffian) and 
paramesonephic (Müllerian) ducts of intermediate mesoderm. Until the seventh 
gestational week, sex of the foetus is indifferent as both ductal systems are present. 
The two pairs of ducts are arranged in tandem, the Müllerian duct arising from 
invaginations in the abdominal cavity to cross the mesonephric ducts medially 
(Figure 1.3). During the seventh week of gestation, the lower portions of the 
Müllerian ducts fuse in females, to form the uterine canal.1 The upper portions 
remain distinct and form the Fallopian tubes. At the same time, the Wolffian ducts 
undergo atrophy in females.  
 
 
 
 
 
 
 
 
Figure 1.4: Organogenesis of the male and female reproductive organs.42 Müllerian 
ducts fuse in the female to become the uterine canal at the 7th week of gestation. 
Wolffian ducts atrophy. 
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Formation of the endometrium itself is initiated by the differentiation of the 
Müllerian duct mesenchyme.43 It is at this point that adenogenesis begins. Simple 
luminal columnar epithelia invaginate to produce buds (Figure 1.4). Once bud 
formation has occurred, tubulogenesis ensues; cellular divisions produce a tube-like 
structure. Subsequent branching and coiling follows, extending deeper into the 
endometrium, until reaching the myometrial junction.  
 
 
 
 
 
 
 
The process is long and only complete at puberty. Neonatal endometrium is 
underdeveloped; luminal epithelium is present with few sparse glands in superficial 
areas. By 6 years of age, endometrial glands have migrated only half-way through 
the endometrium, to reach their end-point in the basal layer at sexual maturation.44 
The migratory ability of epithelia during adenogenesis suggests there are changes in 
the ECM, basement membrane, and mesenchyme-epithelia interactions.43 It is 
important to note the development of endometrial glands arises from the luminal 
surface, however their monthly replenishment is a result of basal glandular activity.  
 
1.1.6: Endometrium conclusion 
The mucosal lining of the uterus is heterogeneous, consisting of epithelia, stroma and 
leucocytes. Each month, human endometrium undergoes differentiation to provide an 
1312 GRAY ET AL.
FIG. 1. Endometrial adenogenesis in the uterine wall of most species.
In many cases where invagination of an epithelium is required for a de-
velopmental process, the first step is bud formation, which involves con-
version of a cuboidal cell to the geometry of a frustrum (a three-dimen-
sional cone with the top removed parallel to the base). This creates a
bulge in a basal portion of the epithelial cells at the point where the
invagination is to occur. The next step is tubulogenesis, which involves
subsequent cell divisions to convert the frustrum into a tube. The simple
tubular glands then begin to il as they roliferate in the stroma toward
the myometrium. The final stage of adenogenesis is the branching mor-
phogenesis of the tubular, coiled glands throughout the stroma, until the
tips r ach the inner circular layer of the myom trium. The overall process
of endometrial adenogenesis is similar to the adenogenesis that occurs
during development of other epitheliomesenchymal organs, such as the
mammary gland, salivary gland, and lung.
entiation and produced adult ewes that displayed the uterine
gland knockout (UGKO) phenotype, which is characterized
by the absence of endometrial glands [15–21]. Partial to
complete UGKO phenotypes were also produced in adult
cows exposed from birth to a combination of progesterone
plus estradiol benzoate (P1E) [16, 22]. Studies of embryo
development in the ovine UGKO uterus showed that a nor-
mal glandular endometrium is essential for peri-implanta-
tion conceptus survival and growth [18, 20, 21]. Consis-
tently, pregnancy rates were also reduced in adult heifers
with reduced endometrial gland numbers that were exposed
neonatally to P1E [16, 23]. In mares, infertility and sub-
fertility are associated with fibrotic lesions in the endome-
trium that are thought to compromise the integrity and func-
tionality of endometrial glands [24]. In sheep [25, 26], cat-
tle [27], and pigs [28, 29], endometrial glands undergo ex-
tensive hyperplasia and hypertrophy during pregnancy,
presumably in response to increasing demands by the de-
veloping conceptus for uterine histotroph [3, 26, 30]. The
precise fate and role of endometrial glands in human preg-
nancy are not known. Nonetheless, functional endometrial
glands appear to be required during the peri-implantation
period and through the first 8 wk after implantation as the
placenta develops [5, 7].
The genetic potential for uterine function during preg-
nancy is defined at conception, but the success of devel-
opmental events regulating endometrial gland morphogen-
esis ultimately determines the functional capacity and em-
bryotrophic potential of the adult uterus [16, 20, 21]. There-
fore, high and unexplained rates of peri-implantation
embryonic losses in humans and livestock may reflect, in
part, unrecognized defects in endometrial adenogenesis or
function induced during critical organizational periods in
the neonate or adult [16, 18, 21]. In women and menstru-
ating primates, the long pre- and peripubertal period, during
which endometrial adenogenesis occurs, and the cyclical
nature of adult endometrial regeneration provide significant
and repeated opportunities for endometrial dysgenesis and
development of pathological lesions that could contribute
to infertility. The purpose of this review is to summarize
current understanding of the developmental biology of uter-
ine glands, with an emphasis on hormonal, cellular, and
molecular mechanisms that regulate endometrial gland
morphogenesis and differentiated function.
COMPARATIVE DEVELOPMENTAL BIOLOGY
OF UTERINE GLAND MORPHOGENESIS
Ontogenesis of Endometrial Glands in Livestock,
Rodents, and Humans
In all mammals, the uterus develops as a specialization
of the paramesonephric or mu¨llerian ducts, which gives rise
to the infundibula, oviducts, uterus, cervix, and anterior va-
gina [31]. The mature uterine wall is comprised of two
functional compartments, the endometrium and the myo-
metrium. The endometrium is the inner mucosal lining of
the uterus and is derived from the inner layer of ductal
mesenchyme. Histologically, the endometrium consists of
two epithelial cell types, luminal epithelium (LE) and glan-
dular epithelium (GE), which are two stratified stromal
compartments including a densely organized stromal zone
(stratum compactum) and a more loosely organized stromal
zone (stratum spongiosum), blood vessels, and immune
cells. The myometrium is the smooth muscle component of
the uterine wall and includes an inner circular layer derived
from the intermediate layer of ductal mesenchymal cells
and an outer longitudinal layer derived from subperimetrial
mesenchyme.
Morphogenetic events common to development of all
mammalian uteri include 1) organization and stratification
of endometrial stroma, 2) differentiation and growth of the
myometriu , and 3) coordinated developme t of the en-
dometrial glands [16, 32]. As illustrated in Figure 1, genesis
of uterine glands involves differentiation and budding of
GE from LE, penetration of uterine stroma by tubes of GE,
and extensive coiling and branching of GE. In humans and
livestock, endo etrial adenogenesis is completed postna-
tally and involves extensive coiling and branching morpho-
genesis (Fig. 2). Consequently, neonatal ungulates (e.g.,
sheep, cattle, and pigs) provide attractive models for the
study of mechanisms regulating these processes [33]. Al-
though adenogenesis is also a postnatal event in rodents,
the adult rodent uterus does not contain the tightly coiled,
branched glands that are characteristic of endometria in
most other mammals. Thus, ungulate and primate species
may provide more relevant models for the study of this
process and related uterine organizational events affecting
the embryotr p ic and func ional capacity of he adult ut r-
us in women and many other mammals.
Sheep and Cattle
The endometrium in adult sheep and cattle consists of a
large number of raised aglandular caruncles, dense stromal
protuberances covered by a simple LE, and intensely glan-
dular intercaruncular areas [25, 34]. Caruncular areas are
the sites of superficial implantation and placentation [25,
31]. In synepitheliochorial placentation, which is charac-
teristic of these ruminants, fusion of placental cotyledons
with endometrial caruncles forms placentomes, which serve
a primary role in fetal-maternal gas exchange and deriva-
tion of micronutrients by the placenta [25, 31, 35]. Inter-
caruncular endometrial areas contain large numbers of
branched, coiled uterine glands that synthesize and secrete
or transport a variety of enzymes, growth factors, cytokines,
lymphokines, hormones, transport proteins, and other sub-
Figure 1.5: Schematic diagram of ade ogenesis. Adenogenesis occurs in four steps: 
1) bud formation; 2) tubulogenesis; 3) coiling and branching; 4) branching 
morphogenesis.43 
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optimum habitat for implantation and blastocyst development. The differentiation is 
non-reversible. If implantation does not occur, a well-known cascade of reactions 
results in menstruation. However, it is the successive proliferative abilities of the 
endometrium that are less well understood; such rapid re-growth would suggest the 
existence of stem cells. 
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1.2: Endometriosis 
Endometriosis is a benign, chronic disorder defined by abnormal growth of 
endometrium outside of the uterine cavity.45 The disease was first defined by the 
general surgeon Thomas Cullen.46 He recognized the two key features: i) the 
presence of endometrial glands and stroma outside of the uterine cavity and ii) 
ectopic endometrial glands and stroma were benign and non-neoplastic in nature.  
 
1.2.1: Epidemiology 
Endometriosis is a significant cause of female infertility and morbidity. A surgical 
examination is required for diagnosis, and for that reason the true prevalence remains 
controversial. In asymptomatic women undergoing tubal ligation, the prevalence is 
thought to be about 4%, (range 1-7%).47 The disease should be suspected in women 
suffering from pelvic pain and primary infertility, present in 50%-60% and 17% 
respectively.48,49 On average it is estimated 10% of reproductive women suffer from 
endometriosis, whether the disease is symptomatic or not.50 
 
1.2.2: Clinical features 
Endometriosis paints a variable clinical picture and clinical features rely largely on 
position of ectopic lesions. Typically, the presenting complaint is pain. This is 
usually chronic, presenting itself in the form of dysmenorrhoea or dyspareunia. Pain 
can be cyclical or continuous, and dull or throbbing. Patients commonly report a 
burning or hypersensitivity, suggesting a neuropathic component.51 Pain is often 
accompanied by bowel symptoms such as dyschezia. However, patients can be 
asymptomatic and the presenting complaint may be a difficulty to conceive. A 
bimanual examination usually reveals focal pain/tenderness and/or a fixed retro-
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verted uterus. Due to the variation of presentation, there is considerable overlap with 
other gynaecological and non-gynaecological diseases such as inflammatory bowel 
disease and depression, making diagnosis challenging. On average it is estimated the 
time from initial symptoms to diagnosis is over ten years.52 
 
1.2.3: Investigations 
Non-invasive investigations such as magnetic resonance imaging (MRI) and trans-
vaginal ultrasound (TVS) have a 80-90% sensitivity and 60-98% specificity at 
detecting ovarian endometriomas but results are less impressive when detecting 
lesions at other locations.53 Ca-125 can be elevated but again this has poor sensitivity 
and specificity.54 Surgical visualisation followed by histological confirmation 
remains the gold standard.55 
 
1.2.4: Pathology and staging 
Endometriosis is an oestrogen dependant disease; lesions consequently wane 
throughout pregnancy, menopause and menstruation. Conversely, there are reports of 
endometriosis being present in males, and women suffering from Turner’s 
syndrome.56,57 However, in both these cases patients were taking exogenous 
hormones, and thus enabled ectopic growth. Ectopic lesions are commonly found on 
the ovaries, fallopian tubes, pelvic peritoneum and bladder. Lesions can be observed 
in distant organs such as the lung, although admittedly these cases are rare.58 Within 
endometriosis, three ‘sub-diseases’ are thought to exist: peritoneal, ovarian and 
rectovaginal.59 Red lesions, ‘powder-burn’, white lesions, ‘chocolate cysts’ and 
microscopic lesions, are all descriptors of this disease’s variable form. Lesions 
comprise endometrial glands and stroma, although appearance is somewhat 
 19 
dissimilar to eutopic tissue (Figure 1.5). Ectopic glands are usually less organised 
and less differentiated. Morphology and histochemical data suggest ‘red’ lesions best 
resemble proliferative eutopic endometrium, proposing these represent early 
implantation and disease.59 Irritation of ‘menstruating’ red lesions leads to an 
inflammatory response within the pelvic cavity, producing fibrosis, which ultimately 
leads to adhesions and distortion of pelvic anatomical structures. Ovarian 
endometriosis typically produces cysts in the form of endometriomas, and recto-
vaginal lesions are rich in smooth muscle with sparse stroma.  
 
 
 
 
 
 
 
 
 
 
 
Histological analysis suggests that increased angiogenesis and neural infiltration are 
also significant features of endometriosis. An Australian group discovered neurons 
are increased in eutopic tissue from women with endometriosis, compared to those 
without.60 This could be the reason why pain is the dominant symptom, and is 
consistent with other work.61-63 The reasons and mechanisms behind increased angio- 
and neurogenesis remain unclear. There are reports of increased angiogenic and 
50µ m 
Figure 1.6: Ectopic endometriotic gland and stroma. Haemotoxylin and Eosin 
staining of a well differentiated ectopic gland, consisting of endometrial epithelia 
and stroma. 
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neural growth factors in the pelvic fluid of women with endometriosis compared to 
those without. This has resulted in a shift in thinking; endometriosis may not be just 
a gynaecological disorder, but indicative of a systemic problem.64,65  
 
The cause of infertility is two-fold. Adhesion formation can result in distortion and 
loss of patency of the fallopian tubes. However, in women without adhesions fertility 
is still reduced; differences on a cellular level in eutopic endometrium are thought to 
be responsible. The American Society for Reproductive Medicine (ASRM) have 
developed a staging system to describe the extent of endometriosis and this correlates 
well with infertility (Table 1.1).  
 
 
1.2.5: Endometriosis and Malignancy 
Although endometriosis is a benign condition, it shares common characteristics with 
malignant cells.66 Like cancer, endometriosis involves ‘metastatic spread’ attaching 
and damaging local and distant tissues.67 A recent study, investigated differences in 
metastatic inducing proteins (MIPs) between eutopic endometrium from patients 
with endometriosis and those without. Immuno-histochemical and polymerase chain 
Stage 1 (Minimal) Findings restricted to only superficial lesions and 
possibly a few filmy adhesions 
Stage II (Mild) As above, some deep lesions are present in the cul-de-sac 
Stage III 
(Moderate) 
As above, plus presence of endometriomas on the ovary 
and more adhesions 
Stage IV (Severe) As above, plus large endometriomas, extensive adhesions 
Table 1.1: ASRM criteria for endometriosis staging 
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reaction (PCR) analysis demonstrated S100A4, S100P, and AgR2 were expressed 
significantly more in endometriosis samples.68 
 
Large studies also suggest endometriosis is associated with a 3-fold risk of 
endometroid and clear cell ovarian cancer.69-70 Akin to its eutopic counterpart, 
ectopic endometrium can also exhibit epithelial abnormalities. In 2002, Prefumo et 
al. histologically reviewed ovarian endometriomas from 339 patients. Complex 
hyperplasia was significantly more prevalent in patients with ovarian cancer than in 
all other cases (P<0.00001), suggesting there is an association between ectopic 
complex hyperplasia and malignancy.71 Despite endometriosis sharing certain traits 
with cancer, it is worth stressing ectopic tissue is non-neoplastic. 
 
1.2.6: Medical management 
Medical management encompasses analgesia and hormonal modulation. Often, 
medical management is empirical treatment, before the diagnosis has been 
confirmed. Some women wish to preserve fertility and avoid hormonal treatment, 
managing symptoms with complementary therapies or non-steroidal anti-
inflammatories (NSAIDs). The effectiveness of NSAIDs remains inconclusive. 
Hormone modulation includes use of the combined oral contraceptive (COC), 
levenorgestrol intra-uterine system (LNG-IUS), or GnRH analogues. The COC is 
often the first line of hormonal management. It has been found to reduce pain scores 
significantly by 75%.72 Danazol, a modified testosterone, is effective at treating 
endometriosis, although its androgenic side-effects make the drug undesirable and it 
has largely been replaced by GnRH analogues. The use of GnRH analogues induces 
a hypo-oestrogenic state. A systematic review of 1821 women taking GnRH 
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analogues showed a pain score improvement of 60-100%.73 Unfortunately, GnRH 
analogues are restricted due to their side effects, as 6% of bone mineral density can 
be lost after only 6 months of therapy.55  
 
A recent development is the use of aromatase inhibitors: aromatase is an enzyme, 
found in many tissues that catalyses the production of oestrogen. It is absent in 
eutopic endometrium from women without endometriosis, barely detectable in 
eutopic endometrium from women with endometriosis, and over expressed in ectopic 
lesions.74 Unfortunately, these remain to be approved by the Food and Drug 
Association (FDA) for the treatment of endometriosis. 
 
1.2.7: Surgical management 
Ideal practice is to surgically remove ectopic lesions at the time of laparoscopic 
diagnosis. Preferably this would be the first intervention, as hormonal therapy should 
be stopped three months prior to diagnostic surgery in order to prevent under-
diagnosis.75 However, there is no general consensus in treating endometriosis; 
therapy very much remains individualised. 
 
Surgical management involves lesion ablation, excision, adhelysis, neurectomies and 
with/without more radical surgery such as total abdominal hysterectomy (TAH) to 
prevent future lesions developing. Although ablative surgery is preferential to 
medical management, as ovarian function is not suppressed, some women still fail to 
respond – either due to incomplete excision or recurrence of the disease. In cases of 
severe pathology, and when fecundity does not wish to be preserved, a hysterectomy 
is indicated in addition to excision of lesions.  
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1.2.8: Aetiology 
The aetiology of endometriosis is complex and is the subject of much debate. Several 
hypotheses are proposed, including retrograde menstruation (Sampson’s theory), 
metaplastic change (Meyer’s theory), embryonic rest cells (Cohnheim’s theory) and 
lymphatic/haematogenous spread (Halban’s theory). No single hypothesis can fully 
explain the disease spectrum, and pathogenesis is most likely to be multi-factorial. 
 
1.2.8i: Sampson’s theory 
Originally proposed in 1927, Sampson’s theory remains the most widely accepted. 
The concept relies on surgical observations made by Sampson and colleagues during 
surgery on women at the time of menses. Menstrual fragments were found to 
emanate from fallopian tubes; Sampson concluded that endometriosis was a 
consequence of retrograde menstruation.76 However, Sampson was unable to 
demonstrate that shed fragments were capable of engraftment and survival outside of 
the uterus: this was later proven in a baboon model by D’Hooge et al.77  The theory 
of retrograde menstruation is supported by other epidemiological data: women with 
Müllerian anomalies and cervical obstruction have an increased risk of developing 
the disease.78 
 
The difficulty is that retrograde menstruation is a natural phenomenon, occurring in 
90% of cycling women.79 Why only 10% go on to develop endometriosis is unclear. 
It is unknown whether shed fragments are pathological to begin with, or whether it is 
exposure to a pathological pelvic cavity that facilitates adherence and growth. As it 
stands, it appears to be a mixture of the two. Therefore, although the theory of 
retrograde menstruation is attractive, it does oversimplify the disease. The theory is 
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deficient at explaining the presence of lesions at distant sites, such as the brain and 
lung, and in the non-menstruating such as post-menopausal women and men.56,58,80,81  
 
1.2.8ii: Meyer’s theory 
Initially, it was assumed endometriosis only existed in the presence of 
peritoneum/mesothelia. Both peritoneum and endometrium share a common 
embryological ancestor – the coelomic cell. In 1924, Meyer et al. proposed coelomic 
epithelia were capable of differentiating into endometrium-like tissue in a process 
known as coelomic metaplasia.82 The ability of coelomic epithelia to differentiate 
into ‘endometrial glands’ under the influence of oestrogen in vitro supports Meyer’s 
hypothesis.83 Scanning electron microscopy and histology have also revealed pelvic 
endometriosis is a serial change in ultra-structural characteristics from normal 
mesothelium.84 
 
It is likely that metaplastic change is only responsible for ‘subtle’ lesions, which are 
visible microscopically. The theory is limited in its ability to explain why most cases 
occur in menstruating women, but can explain the ‘exceptional cases of 
endometriosis’ such as in men or distant sites. More research is needed to validate 
this theory, and it remains merely speculative. 
 
1.2.8iii: Cohnheim’s theory 
In 1877, Julius Cohnheim first proposed the ‘embryonic rest theory’.85 Although the 
term was originally coined to describe carcinogenesis, it has subsequently been 
applied to understanding endometriosis. The theory is similar to Meyer’s theorem, in 
that it relies on an embryological understanding of the reproductive tissue. However, 
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it has a clear distinction; lesions are not a result of peritoneal metaplasia, more they 
are a consequence of aberrant remnant embryonic cells. The Müllerian ducts are the 
embryological pre-cursors to the female reproductive organs (Section 1.1.5). The 
symmetrical and bilateral pattern of endometriotic lesions in the Pouch of Douglas 
has led some to speculate these may be cells of Müllerian origin, as they correlate 
with sites of duct migration.86 It does explain the existence of lesions in men, but it 
cannot account for spread of disease to distant sites. 
 
1.2.8iv: Halban’s theory 
Halban’s theory hypothesises that endometriosis is the result of lymphatic or 
haematogenous spread of endometrial cells. Although appealing when trying to 
explain lesions at distant sites, it cannot elucidate why ectopic tissue is normally 
located in gravity-dependent locations.87 
 
1.2.9: Endometriosis conclusion 
Endometriosis is a highly prevalent debilitating disease, and management remains 
crude. Infertility is the side effect of most therapy, which is un-acceptable to a young 
and already sub-fertile cohort. A greater understanding of endometriosis 
pathogenesis is necessary to produce more sophisticated regimens.  
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1.3: Stem Cells 
The term “stem cell” first appeared in scientific literature as early as 1868, coming 
from the German “Stammzelle” or “family cell”. Ernst Haeckel, a phylogenist, used 
the term to describe a single cell, from which all multicellular organisms were 
believed to originate.88 Although controversial at the time, the concept was later 
echoed by Russian histopathologist Alexander Maksimow and applied to the 
haematopoietic system in 1905.89 It took another 50 years for theory to be replaced 
by fact, as a consequence of the pioneering work by Till and McCulloch.90 
 
1.3.1: Terms and definitions 
Stem cells (SCs) are defined as undifferentiated cells, capable of differentiating into 
other different cell types. They are mandatory for the development and maintenance 
of tissue.91 Current dogma implies a cell needs to possess three qualities in order for 
it to be regarded as a SC.92-94 These are:  
• Clonogenicity 
 This is the ability of single cells to form colonies. 
• Prolonged self-renewal and proliferative potential 
 This refers to the ability of a SC to undergo a high number of passages before 
 cell death. Proliferative potential can also be determined by multiplying the 
 total number of doublings of a single cell by serial passage until senescence.  
• Differentiation potential 
 Differentiation potential, synonymous with potency, is the ability of a SC to 
produce differentiated progeny. There is a scale as to how potent a SC is, and 
this essentially forms a ‘stem cell hierarchy’ (Figure 1.6) Over the course of 
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differentiation, SCs divide and gradually acquire markers and features of a 
differentiated state.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The most potent of all mammalian SCs is the zygote; it has the ability to 
differentiate into embryonic and extra-embryonic tissue, and therefore is 
termed ‘totipotent’. These differentiate to produce pluripotent SCs, which 
have the ability to form tissue from all three germ layers; the endoderm, 
mesoderm and ectoderm.  Pluripotent SCs are found within in the inner cell 
mass of the blastocyst and are commonly referred to as embryonic stem cells 
(ESCs). As organogenesis ensues, SC potency becomes more restricted, 
producing multipotent SCs that give rise only to cell types within that germ 
layer; an example would be mesenchymal stem cells (MSCs). Cells that 
 
Toti-Potent  
Pluri-Potent  
Multi-Potent  
Uni-Potent  
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Figure 1.7 : Schematic diagram of ‘Stem Cell Hierarchy’. The zygote is 
believed to be the most ‘powerful’ SC, capable of differentiating into all cell 
types. As division takes place, the potency of SCs becomes more restricted, 
until finally differentiating into a terminally differentiated phenotype. 
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differentiate into one cell type only are unipotent/precursors. A classic 
example of this is spermatogonia, which differentiate to produce the mature 
spermatozoa. Furthermore, there appears to be an even more restricted stem 
cell; one that is not even glorified with ‘stem cell status’. Some lines of 
evidence suggests there exists a new population of cells, which are an 
intermediate between SCs and differentiated cells; these are referred to as 
transit amplifying cells (TAs). TAs, synonymous with progenitors, undergo 
rapid and repetitive cycles of cell divisions to increase in number. They 
acquire markers of the differentiated cell type, thus losing their ability for 
prolonged self-renewal.95 The term adult stem/progenitor cell (ASPC) 
encompasses stem and progenitor cells in adult tissue. 
 
1.3.1i: Cellular division 
Cellular division is fundamental to understanding SC behaviour. SCs have the ability 
to undergo symmetric and asymmetric cellular division (Figure 1.7). Symmetric cell 
division maintains SC populations and thus facilitates self-renewal and clonogenic 
properties. Two identical daughter cells are produced, or in some cases progeny can 
be TAs. Asymmetric cell division facilitates differentiation. A SC will divide to 
produce an identical daughter cell along with a more differentiated TA cell. These 
TAs will rapidly divide to produce cells with a differentiated phenotype. 
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1.3.1ii: The stem cell niche 
SCs reside in an anatomic structure called the niche. The niche can be regarded as a 
‘buffer environment’, protecting SCs from differentiation, proliferation and apoptotic 
cues. Conversely, the niche is also responsible for stimulating ASCs to proliferate 
and differentiate at times of injury.96 Niches have been identified and characterized 
in organs such as the skin and haematopoietic system.97,98 The niche encompasses all 
surrounding components of the primitive SCs, including neighbouring mature cells, 
soluble components and the ECM. Each niche microenvironment and location is 
specific to its respective SC, and there is substantial evidence to suggest 
mesenchyme dictates epithelial differentiation.99 Unfortunately, when taken out of its 
respective niche, SCs behave differently as to how they would in vivo and herein lies 
the main obstacle to SC research; efforts to study SCs in vitro remain futile. 
However, the advent of 3-dimensional (3D) culture is promising as evidence 
suggests that SCs cultured in a 3D environment behave similarly to how they would 
in vivo.100 The most commercial 3D substrate is MatrigelTM, a gelatinous extract 
Figure 1.8: Schematic diagram of cellular division. 
Symmetrical cell division (a) will give rise to identical SCs or TAs. Asymmetrical 
cell division (b) will result in a TA and a fully differentiated cell. 
 
SC SC 
SC SC TA TA 
SC 
TA Differentiated Cell 
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formed from Engelbreth-Holm-Swann mouse sarcoma cells. The full composition of 
the extract is unknown, causing much criticism. However it is rich in extracellular 
proteins such as laminin and collagen.101 The application of 3D culture is often 
referred to as ex vivo as it is almost a hybrid of in vitro and in vivo research. 
Regardless of its difficulties, 3D culture has opened the door to understanding SC 
behaviour.  
 
1.3.2: Embryonic stem cells 
ESCs, first isolated from the mouse in 1981, are derived from the inner cell mass of 
the blastocyst.102 ESCs are pluripotent and capable of differentiating into all 3 germ 
layers; mesoderm, ectoderm and endoderm. On account of their potency, ESCs show 
great promise for regenerative medicine. However, transplantation of ESCs in vivo 
has led to teratoma formation, and acquisition of ESCs provides an ethical 
headache.102 There are attractive alternatives for autologous transplantation, in the 
form of induced pluripotent stem cells (iPS). The transcription factors NANOG, 
OCT4 and SOX2 are implicated to work synergistically at maintaining ESC 
phenotype.103-105 The importance of these factors is exemplified by their forced 
expression in somatic cells to become iPS, and are therefore key markers of an 
undifferentiated state.106 
 
1.3.3: Adult stem cells 
ASCs, synonymous with somatic stem cells (SSCs), are quiescent undifferentiated 
cells, existing in small numbers in most organs after embryonic development.107 
They are fundamental units for tissue homeostasis, playing a critical part in the 
replenishment of dying cells, and regeneration of damaged tissue. With regards to 
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research and stem cell therapies, ASCs are a more attractive alternative to ESCs as 
acquisition is less controversial. Similarly, in vivo transplantation does not pose the 
risk of teratoma formation. However, ASC research is not without its difficulties and 
these shall be discussed shortly.  
 
1.3.3i: Plasticity 
Between 2000 and 2001, four high profile papers were published suggesting ASC 
plasticity.108-111 It was proposed ASCs can trans-differentiate (acquire broader 
developmental potential), an exciting prospect that heralded enthusiasm for ASC 
therapy. Prior to this, ASCs were believed to be restricted to cell lineages within the 
germ layer they originate, i.e. multipotent only. Clarke et al. labelled neural ASCs 
(ectodermal derived) with β-galactosidase and co-cultured with embryoid bodies. 
Surprisingly, β-galactosidase positive cells were also positive for desmin and myosin 
heavy chain, both markers of myocytes (mesoderm derived). However, two articles 
both published in Nature the following year raised doubt as to whether trans-
differentiation did actually occur. Ying et al. and Tereda et al. aimed to produce 
embryonic-like SCs from co-culture of ESCs with neural ASCs/haematopoietic 
ASCs in vitro.112,113 Resulting embryonic-like SCs had twice the normal DNA 
content, suggesting that fusion had in fact taken place, and there has been a 
subsequent endeavour to repeat the findings of Clarke et al. and others. More 
recently, evidence suggests that a small group of pluripotent stem cells may reside in 
adult tissue in a dormant state. These cells are referred to as ‘very small embryonic 
like’ stem cells (VSEL-SCs) and display pluripotency in vitro.114 It could be these 
cells that are responsible for the results of Clarke et al. As it stands, the jury is still 
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out as to whether trans-differentiation of ASCs is possible, and plasticity remains a 
source of contention amongst stem cell biologists. 
 
1.3.3ii: Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) are multipotent adult progenitor cells, which have 
the ability to differentiate into multiple mesenchymal lineages, including adipocytes, 
osteoblasts and chondrocytes.115 They can be derived from numerous sites, most 
commonly bone marrow, adipose tissue and umbilical cord blood. Despite efforts, 
specific MSC markers are lacking due to poor specificity. Currently, combined 
expression of Stro-1 and CD106 is considered a good candidate MSC marker.116 As 
it stands, MSCs remain the ‘gold standard’ multipotent ASC, and the subject of 
much research by both scientists and clinicians alike.  
 
1.3.3iii: Stem cell markers 
As ASPCs exist in low numbers in mammalian tissue, definitive markers are 
required to identify and enrich cell populations for further study. This poses a real 
difficulty: markers have been identified for some ASPCs, but none are without their 
limitations. The most reliable markers of an undifferentiated state are those of 
NANOG, OCT4 and SOX2. Unfortunately, these are transcription factors and 
located within the cell nucleus; isolation of viable cells is only possible via magnetic 
cell sorting (MACS) or fluorescence-activated cell sorting (FACS) if markers are on 
the cellular surface. Discovery of a specific ASPC surface marker is an active area of 
research. The difficulty is specificity, for example; CD34 is a marker of 
hematopoietic APSCs but it is also present on mature endothelial cells.117 A cell that 
expresses a stem cell marker may not be able to function like a SC, for example, 
 33 
Stro-1+ cells, a putative MSC marker, were unable to demonstrate clonogenicity in 
the endometrium.118 For this reason, SCs are often defined by the presence of 
markers associated with that specific lineage but the absence of markers of a more 
differentiated state. Therefore in order to validate an ASPC marker, in vitro and in 
vivo assays are mandatory. 
 
1.3.4: Stem cell research 
As ASPC markers are unreliable when used in isolation, multiple assays are required 
for validation by characterizing ‘stem cell’ function. Each of these assays is not 
without limitations.  
 
1.3.4i: In vitro assays 
These require an assessment of the defining features of SCs (Section 1.3.1). 
Clonogenicity calculates the ability of putative SCs, when seeded at very low 
densities, to produce colonies of daughter cells. Prolonged self-renewal requires 
serial passaging of cells before cell death and apoptosis. In vitro differentiation is 
performed by culturing cells in media supplemented with various growth factors, 
implicated at inducing differentiation into a specific cell type. Histochemical staining 
along with gene expression confirms differentiation.  
  
1.3.4ii: In vivo assays 
The side population phenotype (SP) could be classified in either of the in vitro or in 
vivo camps. The assay requires FACS to isolate a population of cells enriched with 
SCs, and was first described over 15 years ago when studying bone marrow.119 
Hoescht 33342 is a fluorescent dye that binds to the minor groove of 
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deoxyribonucleic acid (DNA). Uptake of the dye is universal and occurs in all cells. 
However, to be extruded, the process is metabolic and requires a sufficient amount of 
ATP-binding cassette (ABC) transporters. If SCs had DNA damage, this would mean 
all progeny would be affected and it is therefore believed SCs have the ability to 
extrude Hoescht dye as a safety mechanism. The dye emits fluorescence when 
excited by UV light, enabling detection and sorting via FACS. The cells that do not 
possess the fluorescent activity i.e. the cells that have extruded the dye are the side 
population (SP). Cells are counter stained with propodium iodide (PI) to ensure 
viability. There are limitations with the SP assay; Hoescht can be toxic and the effect 
of SP on cell survival can be poor.120 There is also growing caution that dye efflux 
ability is not ubiquitous nor unique to all SCs.121,122 
 
In 1975, John Cairns proposed the immortal DNA strand hypothesis: when SCs 
undergo mitosis, DNA is divided asymmetrically.123 The parent strand is retained by 
SCs and the new strand is selectively segregated to a daughter cell. This would mean 
spontaneous mutations only occur in the newly synthesised strand, preventing 
genetic errors in SCs and potential cancer risk. Although controversial, the principle 
forms the basis for the label retaining cell technique (LRC). Parental DNA is marked 
with a DNA label during S phase of the cycle, typically bromodeoxyuridine (BrdU). 
If cells undergo symmetric mitotic division the DNA label would rapidly be chased 
out of the cell. If however, the cell undergoes asymmetric DNA division, the BrdU 
will segregate in the SC and will still be detectable after a number of divisions. 
Antibodies specific to BrdU can then be used to identify LRCs in tissue. The main 
drawback is that BrdU binds to DNA during replication instead of thymidine. 
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Consequently, mutations occur and BrdU is a recognized health hazard; use of the 
LRC technique in humans is not permitted.  
 
The ‘gold standard’ of in vivo assays is tissue reconstitution. This comprises a series 
of experiments whereby the tissue of interest is reconstituted in a recipient animal by 
transplantation of donor cells.96 Most commonly, bone marrow derived stem cells 
(BMDSCs) are injected intra-venously (i.v.) into immune compromised mice. 
Alternatively, they can be transplanted subcutaneously (s.c.) or under the kidney 
capsule. Animals are later sacrificed and explants examined. Although informative, 
experiments are limited by the absence of a native stem cell niche and the inability of 
the explant to develop into a functional organ.96 
 
1.3.5: Stem cell conclusion 
Despite being a rapidly evolving and exciting field, stem cell research remains in its 
infancy. Due to ethical restrictions, most work focuses on ASPCs. However, study of 
these SCs is not without its own set of difficulties, and no paradigm can be applied to 
explain the behaviour of ASPCs in all tissues. Definitions and theories persist, yet 
each is open to interpretation. The lack of a definitive ASPC marker requires the use 
of in vitro and in vivo assays to characterise putative ASPC phenotype. 
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1.4: Endometrial Stem Cells 
Nearly all somatic organs contain populations of ASPCs. ASPCs were first 
hypothesised to exist in the haematopoietic system, as erythrocytes have a fixed 
lifespan of only 90 days.89 If we compare the haematopoietic system with the 
endometrium; we know human endometrium has an incessant and rapid cycle of 
proliferation every 28 days. Therefore, it would be logical to assume an ASPC is also 
responsible for the maintenance of this tissue.  
 
1.4.1: Early work  
Prianishnikov was the first to consider endometrial ASPCs. In 1978, he proposed 
endometrial ASPCs reside in the deep basal layer, and their differentiation is marked 
by changes in hormonal receptivity.124 Prianishnikov suggested hormone 
independent ASPCs initially differentiate into oestrogen dependent cells, then on to 
become both oestrogen and progesterone dependent. Terminally differentiated cells 
were progesterone dependent only, and had a limited lifespan (Figure 1.8).   
 
 
 
 
 
 
 
Figure 1.9: Hypothesised hormonal receptivity of endometrial ASPC. Endometrial 
ASPCs are believed to be devoid of oestrogen and progesterone receptors, acquiring 
such receptors during differentiation. 124 
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The theory was not supported until 1991. Padykula et al. were able to demonstrate 
zonal differences in proliferative ability in the endometrium; zones I and II had high 
mitotic activity, whereas zones III and IV had reduced activity, suggesting the 
existence of a group of quiescent ASPCs in the basal layer (Figure 1.9).125 Similar 
results were observed by Brenner et al., using the more specific proliferative marker 
phospho-histone-H3 (PPH3), in macaque endometrium.126  
 
 
 
 
 
 
 
There certainly is indirect evidence to support the combined theory of Prianishnikov 
and Padykula et al. Electron microscopy has revealed endometrium is able to expand 
between 4-7mm within 4-10 days, and growth is initiated from the necks of ‘de-
nuded’ glands in the basalis.36,127 
 
Also, a Japanese PCR study investigated the monoclonal composition of endometrial 
tissue.128 The authors examined CAG tags on the inactivated X chromosome of 
endometrial epithelia. It was discovered glands within a 1mm2 area were 60% likely 
to be monoclonal, suggesting the presence of a single progenitor cell.   
Figure 1.10: Hypothesised location of ASPC in human endometrium.125 
Schematic diagram demonstrating the hypothesised location of endometrial ASPCs. 
Reduced mitotic activity in the basalis layer (zones III and IV) is consistent with 
stem cell activity. 
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1.4.2: Clinical evidence 
Electro-surgical ablation aims to remove all endometrium from the uterine cavity. 
Nonetheless, complete re-growth has been found as little as 4 months after 
therapy.129 Furthermore, post-menopausal (PM) endometrium loses the functional 
layer and only the basalis remains. However, if given sufficient exogenous 
hormones, it is capable of regenerating a new differentiated functionalis that can 
support a viable pregnancy to term.130 Similarly, Asherman’s syndrome is defined as 
loss of endometrium and patency of the uterine cavity, secondary to adhesions. 
Under the influence of oestrogen, injection of autologous bone marrow cells into the 
uterine cavity has been reported to stimulate endometrial re-growth, sufficient to 
support in vitro fertilisation (IVF) pregnancy.131  
 
In addition; bone, cartilage, smooth and striated muscle have all been observed in 
human endometrium, mainly in stromal sarcomas.132-134 The endometrium can also 
be a source of extra-medullary haematopoiesis, albeit in rare circumstances.135 A 
defining feature of MSCs is their ability to differentiate into mesodermal tissue when 
given external prompts.115All findings considered, there could be a multipotent SC in 
the endometrium that has the ability to generate erroneous tissue, if given 
pathological stimuli.  
 
1.4.3: Endometrial adult stem/progenitor cell assays 
1.4.3i: In vitro assays 
Despite early data suggesting ASPC existence, conclusive evidence did not emerge 
until 2004. Chan et al. demonstrated clonogenicity of endometrial derived cells, 
definitive of a SC phenotype.136 Endometrial epithelial and stromal cells were seeded 
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at clonal density, and cloning efficiency (CE) was assessed after 15 days in culture. 
Two types of colonies developed; large tight packed ones, consisting of over 4000 
cells, and more common smaller dense colonies. CE of epithelia was 0.22 ± 0.07%. 
Stroma had an overall CE of 1.25 ± 0.18%.136 Large colonies could also undergo 30-
32 population doublings before cell senescence.137 The authors hypothesised that 
smaller colonies represented TAs as they were more common and had limited self-
renewal. Larger colonies were believed to represent primitive ASCs; these were less 
common and more proliferative. Other authors have produced similar results in 
stroma, from normal and pathological endometrium.138-140 Serial passage of putative 
epithelial and stromal ASPCs before senescence is reported as 12 and 15-30 
respectively.139,141 
 
The idea that the endometrium, a somewhat disposable tissue, could be a source of 
other cell types has captured the imagination of stem cell biologists. As mentioned 
previously, endometrium derives from intermediate mesoderm (Section 1.1.5). 
Therefore, if multipotent it should be able to produce other mesoderm cells types 
such as adipocytes, osteoblasts, chondrocytes and skeletal muscle. A number of 
studies suggest endometrial stromal adult stem/progenitor cells (ESt-ASPCs) from 
intact endometrium are capable of multi-lineage differentiation in vitro, being able to 
differentiate into fat, bone, cartilage, and skeletal muscle. 138, 141-149 In addition, ESt-
ASPCs have demonstrated plasticity by trans-differentiation into neural and 
pancreatic cells both in vitro and in vivo.146,150,151  
 
Meng et al. were the first to publish similar results using ESt-ASPCs obtained from 
menstrual blood.152 Cells were capable of differentiation into adipocytes, osteoblasts, 
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chondrocytes, cardiocytes, myocytes and endothelia. ESt-ASPCs from menstrual 
blood were also capable of trans-differentiation into endodermal and ectodermal 
tissue such as hepatocytes, pulmonary epithelia and neurones. ESt-ASPCs in 
question were mononuclear and demonstrated positive immuno-reactivity for CD90, 
CD73 and CD103, but were devoid of CD34 and CD45 suggesting a mesenchymal, 
not haematopoietic origin. Others have demonstrated similar features of ESt-APSCs 
derived from menstrual blood, and this has sparked a campaign of interest in ESt-
ASPCs as a source of SC therapy.153-159 Animal models of Duchenne muscular 
disease, stroke, diabetes and critical limb ischemia suggest ESt-ASPCs improve 
outcome.150,151,154,159 In one phase I clinical trial of 4 patients with multiple sclerosis, 
no adverse effects have so far been documented.160 Similarly, a phase II double-blind 
clinical trial using menstrual ESt-APSCs for the treatment of congestive heart failure 
is underway, and another for the treatment of critical limb ischemia has just been 
launched.161,162 Interesting, the use of ESt-ASPCs for endometrial diseases, such as 
Asherman’s syndrome, is less heavily researched.  
 
Most work assessing multipotency of endometrial cells has focused largely on the 
stromal population, probably on account the greater abundance in endometrial tissue, 
and the associated difficulties with epithelial culture. To the best of our knowledge, 
only three studies have attempted to differentiate primary endometrial epithelial adult 
stem progenitor cells (EEp-ASPCs). In 2009, Gargett et al. were able to demonstrate 
unipotency, by differentiating EEp-ASPCs into CK+ gland-like structures, in 3D 
MatrigelTM.143 Unfortunately, an assessment of multipotency was not possible, as 
epithelial cells were unable to grow to confluency. This may be because authors were 
using colony-forming units from EpCAM+ endometrial epithelia, a notoriously small 
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subpopulation of cells. Two papers by Cervello et al. suggested that endometrial 
epithelial SP are multipotent, by demonstrating differentiation of these cell types into 
adipocytes and osteoblasts in vitro.141,147 Cells were passaged up to 15 times and 
cultured in appropriate induction/non-induction media. After 2 weeks in culture, 
EEp-ASPCs in adipogenic induction media demonstrated the presence of Oil Red O 
lipid vacuoles, unlike cells in control media. Likewise, EEp-ASPC cultures in 
osteogenic induction media demonstrated positive immuno-reactivity for bone 
sialoprotein (BSP) when compared to non-induced cells. Published figures are open 
to criticism, as despite the presence of lipid vacuoles, differentiated EEp-ASPCs are 
spindle-like and do not display the characteristic rounded morphology typical of 
adipocytes (Figure 1.10). Similarly, PCR was semi-quantitative and therefore 
comparisons cannot easily be made. Curiously, the same authors were able to 
demonstrate unipotency of endometrial SP cells in vitro.141 EEp-ASPCs and ESt-
APSCs were injected under the mouse kidney capsule (mesodermal derivative) and 
generated endometrial tissue; cells did not differentiate into kidney parenchyma. 
Therefore, an assessment of the differentiation potential of endometrial epithelia still 
remains elusive, tenuous and lacking. 
 
 
 
 
 
 
 
 
a b 
Figure 1.11: Adipogenesis of human endometrial epithelial SP cells141 
Epithelial SP cells cultured in adipogenic media displayed Oil Red O Lipid vacuoles 
(a), see arrow. However, morphology was dissimilar to control adipocytes (b). 
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1.4.3ii In vivo assays 
SP cells have been isolated in epithelia and stromal fractions from healthy and 
cancerous endometrium.141,147,163-9 Higher numbers have been reported in menstrual 
and proliferative phases, consistent with endometrial ASPC function.163,164 A mouse 
model was able to confirm that stromal SP cells significantly increased 6 hours after 
endometrial injury, and was dependent upon the presence of oestrogen.168 There does 
not appear to be any change in SP numbers throughout a woman’s life, again 
consistent with the dormant nature of ASPCs.147 Studies have also assessed the 
clonogenicity, proliferation and differentiation potential of these cells in vitro and 
results appear to be consistent with SC theory.141,147,163,164,166,167 Tissue reconstitution 
in vitro has proven more difficult at regenerating endometrial tissue.141,147 However, 
tissue reconstitution has been successful at generating endothelial cells and mature 
blood vessels in the mouse kidney.167 Microarray studies show up-regulation of 44 
genes and down-regulation of 14 in SP cells when compared to non-SP, suggesting a 
common cell fate.147 However, there is also evidence to suggest SP cells are 
heterogeneous. Reduced expression of epithelial and stromal markers CD9 and 
CD13 have caused some authors to claim that SP cells are representative of cells in 
an undifferentiated state.163 However, others have cast aspersions on this 
observation, and question whether in fact a large proportion of SP cells are blood 
borne. Immuno-staining with the SP marker, ABCG2+ has located these cells in 
basal epithelia and as CD31+ endothelial cells throughout the endometrium.164,167 
 
Three papers have demonstrated the presence of LRCs in endometrium. The first, by 
Chan et al., pulse labelled mouse endometrium with BrdU.170 After an 8 week chase, 
only 3% of epithelial nuclei were BrdU+. These were in the luminal epithelia and 
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dual labelling immuno-fluorescence revealed cells were negative for ER-α. 
Conversely, 6% of stroma were LRCs; these were located just below the luminal 
epithelia, at the endo-myometrial junction or near blood vessels. Interestingly 16.7 ± 
0.02% of these cells were ER-α negative. Co-labelling with CD45 and CD31 
revealed these cells were not leucocytes nor endothelia. BrdU+ cells surrounding 
blood vessels were positive for α-SMA and it is probable these cells represent 
pericytes. The same authors demonstrated oestrogen drives epithelial LRC 
proliferation in juvenile development, but has a minimal role in epithelial and 
stromal LRC cyclical regeneration, suggesting that neighbouring BrdU-/ER-α+ cells 
release paracrine factors to mediate an LRC response.171 Cervello et al. also had 
difficulties in detecting epithelial LRCs after a 3 week chase. Stromal LRCs were 
detected in similar numbers and 0.2 ± 0.1% of stromal LRCs co-expressed OCT4, a 
marker of an undifferentiated state.172 All considered, as BrdU+ epithelia were lost 
soon into the chase period, it could be that epithelial regeneration relies on the self-
duplication of a mature epithelial cell type. Conversely, it may be that the LRC 
technique is not sensitive enough to label endometrial epithelial cells with an ASPC 
phenotype.  
 
In addition, as BrdU is toxic, the subject for these assays is mouse endometrium. 
Mice do not undergo a menstrual cycle; they undergo an estrous one. The cycle is 
still dependent upon the female sex hormones oestrogen and progesterone, however 
the cycle is shorter, typically 4-5 days and endometrial tissue is not shed: it is 
reabsorbed. Although some authors champion the mice as a sufficient model to study 
endometrial ASPC behaviour, one cannot be certain it is applicable to understanding 
ASPCs in human endometrium. 
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As touched on previously, tissue reconstitution has been attempted in vivo by animal 
xenograft-transplants.141,147,167 Results have demonstrated an ability to produce 
endometrial tissue but explant survival is poor. Cervello et al. also investigated the 
relationship between stromal and epithelial ASPCs.147 When stromal SP cells were 
transplanted under the kidney capsule in mice, only endometrial stroma was formed. 
A similar observation was observed when only epithelial SP cells were transplanted. 
Endometrial-like tissue was only generated when both these populations were 
combined. This would suggest that two distinct ASPCs exist; a stromal and an 
epithelial ASPC.  
 
1.4.4: The endometrial stem cell niche 
It would be sensible to assume that the endometrial stem cell niche is confined within 
the basal layer of the endometrium; this is the only layer that persists throughout all 
stages of the menstrual cycle and menopause. Indeed, there is evidence to suggest the 
clonogenicity of putative endometrial stem cells remains constant throughout all 
stages of the menstrual cycle and in the post-menopausal.173 In addition, ABCG2+ 
cells, representative of the SP, have been found in basal epithelia.164 However, the 
same authors found ABCG2+ cells in stroma throughout the endometrium. This 
finding is supported by the fact cells with SC activity are present in menstrual blood, 
indicating ASPCs may also reside in the functional layer.152 Cells positive for the 
marker of an undifferentiated state, SOX2 were located in peri-vascular stroma.174 
Likewise, basal stroma were also found to be positive for haematopoietic ASPC 
maker c-kit.175 Location of the stem cell niche in other tissues has relied on the LRC 
phenotype. As previously discussed, in the case of endometrium, results are not 
necessarily applicable to human physiology. Epithelial LRCs are located at the 
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luminal epithelia and it is likely, as mice do not have a basal or functional layer, that 
this is the source of endometrial regeneration.170 Stromal LRCs were observed in 
three groups; around blood vessels, at the endo-myometrial junction and also under 
the luminal epithelia. It could be possible that there exists more than one niche for 
each APSC; it could also be possible that each of these LRCs represent a different 
APSC population, each with its own respective niche.  
 
As mentioned in Section 1.3.1, the niche senses the need for tissue replacement. One 
could be forgiven in thinking that stimulatory signals involve changing 
concentrations of oestrogen and progesterone. However, this is not necessarily the 
case. BrdU+ epithelial cells were negative for ER-α, whilst surrounding epithelia 
were positive. Similarly, only 15.7% of stromal LRCs had positive immuno-
reactivity for ER-α and yet both cells were able to proliferate under the influence of 
oestrogen.170 Schuring et al. substantiate these findings, as expression of ER-α and 
ER-β is believed to be down-regulated in clonal stem cell cultures.176 Therefore, 
endometrial ASPCs may not be subject to direct stimulation of the sex steroids, but 
rather depend on paracrine mechanisms within the stem cell niche.  
 
1.4.5: Bone marrow as a source of endometrial ASPCs 
Recent studies suggest the bone marrow (BM) may be responsible for endometrial 
regeneration. Bone marrow derived cells (BMDCs) have been shown to circulate and 
contribute to repopulating neurons, hepatocytes, and cardiomyocytes.177-179 
 
In 2004, Taylor et al. was able to demonstrate chimerism in endometrial glands and 
stroma of four women who received human leukocyte antigen (HLA) mismatched 
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bone marrow transplants.180 Frequency of chimerism in CD45- cells ranged from 
0.2% to 52% and there was an association with time from transplant. Whole glands 
and neighbouring stroma were of donor origin, suggesting clonal expansion of a 
common ancestor. On account of the limited numbers, it could not be determined 
whether this was significant. The study was also flawed in that the results were 
observed in a pathological model; endometrium and bone marrow from recruited 
patients were both pathological. 
 
BM as a source of endometrial regeneration is supported by the ability of BM 
derived MSC to produce ‘decidua-like’ stroma after activation of the PKA pathway 
in vitro.181 Similarly, BM derived cells have been found in the decidua of normal 
murine pregnancy.182 Co-culture of BMDC with endometrial stromal cells and 
oestrogen stimulation resulted in CK+ endometrial epithelial like cells.183 However, 
this study is controversial as it is questionable as to how efficient the filtration 
process, aimed at preventing epithelia contamination, actually was. A more elegant 
transgenic study allowed green fluorescent protein (GFP) labelling of donor CD45 
cells.184 These were transplanted into wild mice, and endometrial luminal epithelia 
were found to be GFP+. Unexpectedly, GFP+ endometrial cells rose dramatically to 
82% in one pregnant mouse. These findings, together with the knowledge that LRCs 
and SP cells are located peri-vascularly, support that BM could be a potential source 
of endometrial regeneration. However, it is questionable as to whether BM is the sole 
source of endometrial regeneration or merely a replenishing ally. In one study, male 
BMDCs were transplanted i.v. into female mice. Fluorescence in situ hybridization 
(FISH) analysis of mice endometrium, found Y-chromosomes were present in only 
0.0002% of CD45-/F4/80- epithelial cells and 0.0003% of CD45-/F4/80- stromal 
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cells.185 Likewise, a Spanish study of women who received BM transplant from male 
donors, revealed Y-chromosomes were found in the non-SP population.186 There is 
conclusive evidence to suggest BM is a source of endometrial regeneration but 
contribution is low. It is likely BM is implicated in endometrial repair after times of 
injury such as ablation, and in the formation of the decidua, when the endometrium 
requires ‘extra-assistance’; a resident ASPC is most likely to be responsible for 
cyclical restoration. 
 
1.4.6: Stem cells in endometriosis 
Although stem cells are essential for tissue replenishment, they can have a sinister 
alter ego; cancer stem cells are known to exist in a number of tissues. Since 
endometriosis shares many common features with malignancy, it is possible that 
‘endometriosis stem cells’ also co-exist. The implication of stem cells in 
endometriosis does not refute nor object any pre-existing concept. In fact, it can be 
applied to, and work synergistically with each hypothesis in turn.  
 
In the case of Sampson’s theory, retrograde menstruation of stem cells could be 
responsible. This would explain why lesions are not ‘lost’ with each menstruation. It 
also justifies lesion proliferation and high recurrence rates. Endometrial stem cells 
are hypothesised to exist in the basal layer. We know that women with endometriosis 
shed more of their basal endometrium than healthy controls.187 However, there is one 
weakness with this collaboration of theories: if endometrial stem cells were thrust 
into the pelvic cavity, they would inevitably be taken out of their respective niche 
and presumably into the niche of another organ. If this were so, it is unknown why 
ASPCs would not differentiate into tissue from that respective niche, for example 
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ovary or peritoneum. It could be that healthy endometrial stem cells are unipotent. It 
could also be that retrograde menstruation involves the expulsion of multipotent 
ASPCs in the majority of women. These could contribute to surrounding tissue, 
going unnoticed; but in the 10% that do develop endometriosis, these could be 
‘pathologically committed,’ and it is this commitment step that is integral to 
pathogenesis. We know that ESt-ASPCs are multipotent in cases of health and 
endometriosis, but the same cannot be said for EEp-ASPCs. 
 
Likewise, the stem cell theory also supports that of Meyer, Halban and Cohnheim. 
With respect to Meyer’s theory, bone marrow is a source of endometrial regeneration 
and is also recruited in endometriotic lesions; coelomic metaplasia could be from 
these cells.185 Furthermore, smoking inhibits bone marrow recruitment and appears 
to have a protective effect upon endometriosis.188,189 The aetiology of endometriosis 
is controversial and theories remain plentiful; nonetheless the concept of pathological 
stem cells is applicable to all. 
 
1.4.7: Putative Endometrial APSC Makers 
Co-expression of CD146 and platelet derived growth factor–receptor β (PDGF-Rβ) 
is currently being championed as an ESt-ASPC marker.149 FACS sorted 
CD146+/PDGF-Rβ+ cells had significantly greater colony-forming capacities than 
CD146-/PDGF-Rβ– cell populations, 7.7 ± 1.7% verses 0.7 ± 0.2% respectively 
(p=0.0001).149 Similarly, CD146+/ PDGF-Rβ+ cells produced more large colonies 
with densely packed cells and a high nuclear:cytoplasmic ratio, thought to be 
representative features of ASCs. More lately, W5C5 has also been heralded as a 
putative ESt-ASPC marker.190 W5C5+ cells represent 4.2 ± 0.6% of endometrial 
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stromal cells, which are located peri-vascularly and have greater clonogenicity than 
depleted counterparts.  
 
Until very recently, efforts to describe an EEp-ASPC marker remained forthcoming. 
Data from our laboratory suggest stage specific embryonic antigen -1 (SSEA-1) may 
be a potential candidate. SSEA-1 is a cell surface glycan and present on mouse 
ESCs. Expression is lost during ESC differentiation, and therefore its presence 
signifies cells in an undifferentiated state.191 Expression is not unique to ESCs, as it 
has also been found to be an ASPC marker in the human nervous system.192 
 
Screening endometrial full thickness samples throughout the menstrual cycle 
demonstrated that SSEA-1 immuno-reactivity was specific to epithelia only. In 
addition, staining intensity was significantly greater in proliferative endometrium 
than in secretory (unpublished data). Conventional ASPC assays have demonstrated 
SSEA-1 enriched cell populations have a greater propensity to produce gland-like 
structures in 3D culture, when compared to SSEA-1 depleted fractions (Figure 1.11). 
However, work on SSEA-1 phenotype remains preliminary and ASPC assays are 
required to validate SSEA-1 as a suitable EEp-ASPC marker.  
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1.4.8: Endometrial Stem Cell Conclusion 
Indirect evidence suggests that the endometrium is home to a group of ASPCs, and 
this has been supported by functional assays. In vitro studies have demonstrated a 
group of epithelial and stromal cells with high clonogenicity, multipotency and 
prolonged self-renewal. SP cells, LRCs and markers of differentiation are all present 
within the endometrium. However tissue reconstitution of endometrium in vivo 
remains disappointing. A greater understanding is required, but is dependent upon 
the acquisition of endometrial ASPC markers. Co-expression of CD146/PDGF-Rβ 
and W5C5 are representative of putative ESt-ASPC markers. ESt-ASPCs are unable 
to generate endometrial glands and tissue as a whole, suggesting the existence of a 
distinct EEp-ASPC. Recently, SSEA-1 was proporsed as a potential EEp-ASPC 
marker. In order to validate this hypothesis, ASPC assays need to be employed, 
comparing epithelial SSEA-1+ and SSEA-1- fractions in the endometrium.   
FACS analysis of epithelial cells dual labelled for SSEA
-1 and CD9  (C) Epithelial cells grown in monolayer were labelled with PE-SSEA-1 and 
FITC-CD9 and sorted by FACS into a SSEA-1+/CD9+ fraction and a SSEA-1-/CD9+ 
fraction. Representative dot blot of the analyses (left panel), re-analysis of the SSEA-1+/
CD9+ sorted fraction (middle panel) and re-analysis of the SSEA-1-/CD9+ (right panel). 
(D) TRAP assay on the SSEA-1+/CD9+  and SSEA-1-/CD9+ fractions with HeLa as con-
trol. Data are mean+/- SEM, n=6 
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(F) Spheroid formation in 3D cu ture is a function of SSEA-1 expression Epithel al cells grown in mon layer for   
between 4-7 days were sorted into SSEA-1+ and SSEA-1– fractions by MACS prior to seeding into Matrigel under 
serum-free defined conditions. After 10 days in culture the number of spheroids, with a diameter of > 50 um, were 
scored. (A) Phase micrograph of SSEA-1– cells in Matrigel and (B) SSEA-1+ cells in Matrigel. (C) Bar graph show-
ing the number of spheroids produced for SSEA-1– and SSEA-1+ as a percentage of cells seeded; n=10 for each 
group, mean +/- SEM. Scale bar, 100 um. 
Fig 3 
 Proliferation of SSEA1 expressing cells. (A) Epithelial cells grown in monolayer were analysed for the expression of 
SSEA 1 and Ki67. Cells were l belled with PE-anti-SSEA 1 and then fixe  with 2% paraformaldehyde in PBS. Cells 
were then permeabilised with 0.1% triton X100 in PBS, labelled with FITC-anti-Ki67 and finally subjected to  flow 
cytometry Representative dot blot (left panel) and histogram (middle panel) showing dual labelling for SSEA 1 and 
Ki67 and a representative histogram showing CD9 expression. Data are mean +/- SEM; 56.2+/- 3.9%; n=3. CD9 ex-
pression was >85%. (B)  Epithelial cells enriched for SSEA 1 by MACS analysed by SDS-PAGE and immunoblotting 
for phosphohistone H3 with actin as loading control (left panel) and quantification of the immunoblot by ImageJ (right 
A F 
Gel electrophoresis; (E) Markers of pluripotency on SSEA-1+ enrich d samples, positive 
control = ESCs, Positive control for CD133 = HT29, negative control =NTC 
Fig Characterisation of epithelial cells enriched by for SSEA-1. Epithelial cells grown in 
monolayer expressing SSEA-1 were purified by MACS. Equal amounts of protein were 
analysed by SDS-PAGE followed by immunoblotting for SSEA-1, with both actin and CD9 
as loading controls. This is representative of three separate experiments each with four pairs 
of samples analysed. The SSEA-1 enriched fraction was strongly reactive for SSEA-1 as 
assessed by immunoblotting compared with the SSEA-1 depleted fraction and both frac-
Figure 1.12: Spheroid formation of SSEA-1 enriched and depleted cell 
populations. SSE -1 enriched (b) and depleted (a) cell populations were cultured in 
3D media to produce gland-like structures. SSEA-1 enriched populations had greater 
propensity to produced gland-like structures/organoids (unpublished data). 
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Chapter Two:  
RESEARCH AIMS 
 
Recently, SSEA-1 has been proposed as a putative stem cell marker in endometrial 
epithelia. This work aims to validate the stem cell behaviour of SSEA-1 human 
endometrial cells, by specifically looking at its differentiation potential. 
 
2.1 Assessment of unipotency in vitro 
 SSEA-1 enriched cells have a greater propensity to produce ‘gland-like 
 structures’ in  3D culture. A thorough immuno-histochemical analysis 
 comparing in vivo endometrial glands from pre- and post-menopausal tissue, 
 with gland-like structures generated from 3D culture will be conducted. This 
 will establish whether the structures really are representative of endometrial 
 glands. The results therefore will confirm, for the first time, an endometrial 
 epithelial cell subpopulation with progenitor function. 
 
2.2 Assessment of multipotency in vitro 
 Mesenchymal stem cells are capable of differentiating into different cell types 
 of mesodermal origin. Previous authors have shown that human ESt-ASPCs 
 have the capacity to differentiate into these cell types. This study aims to 
 establish whether SSEA-1 enriched and depleted epithelial cells have the 
 same potency.  
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2.3 Assessment of pluripotency in vitro 
 Eutopic and ectopic endometrium from women with endometriosis contains 
 increased neural fibres when compared to normal controls. The origin of 
 these nerve fibres is unknown. It is possible they are the result of aberrant 
 differentiation of a pluripotent endometrial stem cell. ESt-ASPCs can trans-
 differentiate to produce cell types from endodermal and ectodermal germ 
 layers. This work will also investigate whether SSEA-1 enriched and 
 depleted epithelial cells possess the same plasticity. 
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Chapter Three: METHODS 
3.1: Overview of Study Design 
3.1.1: Unipotency experiments 
  
Figure 3.1: Flow diagram of study design to assess unipotency of SSEA-1 
enriched cell populations 
Endometrial Biopsies 
Fixation 
Preparation of the Slide 
Processing 
Embedding 
Image Analysis 
Epithelial Cell Isolation Tissue Sections 
3D Cell Culture 
Harvesting 
Immuno-histochemistry Haematoxylin & Eosin Staining 
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3.1.2: Multipotency experiments
Endometrial Biopsies Human Mesenchymal Stem Cells 
Epithelial Cell Isolation 
MACS 
SSEA-1+ cells SSEA-1- cells 
Differentiation 
Adipogenesis Osteogenesis Control 
Analysis 
Fixation RNA Extraction 
RNA Quantification 
cDNA Synthesis 
qRT-PCR 
Statistical Analysis 
Staining 
Oil Red O ALP 
Image Capture 
Figure 3.2: Flow diagram of study design to assess multipotency of SSEA-1 
enriched and depleted cell populations 
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3.1.3: Pluripotency experiments
Trans-differentiation 
SSEA-1+ SSEA-1- 
Endometrial Biopsies 
Epithelial Isolation 
MACS 
Immuno-fluorescence 
Neurogenesis Control 
PGP9.5 
Image Analysis 
Statistical Analysis 
 Figure 3.3: Flow diagram of study design to assess pluripotency of SSEA-1 
enriched and depleted cell populations 
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3.2: Tissue Collection 
3.2.1: Ethics approval 
Collection of human endometrium was approved by Liverpool Adult Ethics 
committee (LREC references; 09/H1005/55 and 11/H1005/4). All samples were 
taken from women who had given informed and written consent (for letters of 
approval from the ethics committee, see Appendix I). 
 
3.2.2: Study groups 
Endometrial biopsies were taken from three different groups of patients. All 
participants were recruited at the Liverpool Women’s Hospital (LWH).  
 
Fertile Control Group 
Inclusion Criteria 
• Women aged between 18-51years 
• Able to give informed voluntary consent 
• Undergoing laparoscopy or hysterectomy for benign 
conditions at LWH 
Exclusion Criteria 
• Pregnant, currently/within the last three months 
• Breastfeeding, currently/within the last three months 
• Exogenous hormonal therapy within the last three months 
• History of infertility 
• History of endometrial pathology 
• History of endometriosis 
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Endometriosis group 
 Inclusion criteria 
• Women aged between 18-51 years 
• Able to give informed voluntary consent 
• Undergoing laparoscopy or hysterectomy for benign 
conditions at LWH 
• Surgical diagnosis of active endometriosis 
Exclusion criteria 
• Pregnant, currently/within the last three months 
• Breastfeeding, currently/within the last three months 
• Exogenous hormonal therapy within the last three months 
  
 Post-menopausal group 
  Inclusion criteria 
• Women aged over 51 years 
• Able to give informed voluntary consent 
• Undergoing laparoscopy or hysterectomy for benign, non 
endometrial conditions, such as uterine prolapse, at LWH 
• Last menstrual period over 12 months ago 
Exclusion Criteria 
• Exogenous hormonal therapy within the last three months 
• History of endometrial pathology 
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3.2.3: Identification and recruitment of participants  
Theatre lists were scanned on a daily basis to highlight potential candidates. From 
there on, patient notes were studied and brief consultations with patients helped to 
clarify whether specific criteria were met. Only Good Clinical Practice (GCP) trained 
personnel took consent to ensure it was fully informed, competent and voluntary. 
Both verbal and written consent was obtained. Patient demographic data such as age, 
weight, height, body mass index, smoking history, parity, history of miscarriage and 
termination of pregnancy, cycle length, days of bleeding, LMP, reason for surgery 
and endometriosis stage (if relevant) were also collected from each participant (for 
examples of Patient Information, Consent and Data Sheets, see Appendix I). 
Surgeons were also asked to confirm the presence/absence of active endometriosis 
and stage (if relevant) at the time of performing the procedure. 
 
3.2.4 Biopsy collection 
Biopsies were taken in theatre to ensure the procedure was carried out in a sterile and 
safe manner. Only trained professionals took endometrial samples. Two types of 
samples were collected: full thickness and pipelles. 
 
3.2.4i: Full thickness samples 
Full thickness samples were collected when a hysterectomy was performed. Once the 
uterus was removed, it was immediately transferred to a surgical trolley with the 
anterior side facing downwards. A shallow incision was made in the midline from 
the fundus running inferiorly to the cervical canal on the posterior aspect (Figure 3.4, 
line a). This was repeated until the uterine cavity came into view, exposing the 
endometrial tissue. This task was assisted with the use of a surgical blade (size 22, 
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Figure 3.4: Full thickness samples. Full thickness samples were obtained by first 
opening the pelvic cavity (a), a parallel incision was then made to withdraw a 
‘wedge’ sample (b). The endometrium was then visualised and removed via a final 
incision (c). 
Swann-Mortem, Sheffield, UK) and Bonney Forceps (Thermo Fisher, Runcorn, UK). 
From there on, a second incision was made (b) to remove a full thickness section 
containing both myo- and endometrium. The endometrium was visualised and a final 
incision was made into the myometrium running approximately 1-2mm from the 
endo-myometrial junction (c). This section would be used for dating of the biopsy 
and immuno-histochemical analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
For tissue culture and ribonucleic acid (RNA) extraction, a second approach was 
used. A blade was run along the inner aspect of the uterine cavity, removing any 
endometrial fragments. Care was taken not to disrupt the endo-myometrial junction, 
to avoid contamination with myometrial cells.  
 
 
a b 
c 
Myometrium Endometrium 
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3.2.4ii: Pipelle samples 
In cases when the uterus was not removed, pipelle biopsies were obtained. This 
involved the use of an endometrial sampler at the beginning of the operative 
procedure. Pipelle sampling is a very low risk procedure and normally carried out in 
an outpatient setting.193 Briefly, patients were placed in the lithotomy position and a 
speculum was used to visualise the cervix. A tenaculum was applied to the anterior 
lip of the cervix, providing gentle traction and minimising the risk of perforation. 
The pipelle (Laboratoire C.C.D., Paris, France) was then introduced into the uterus 
via the cervical os and advanced until gentle resistance was felt. The inner piston of 
the pipelle was withdrawn, creating a vacuum effect and removing the endometrial 
lining (Figure 3.5). The pipelle was rotated 360°C and moved up and down the 
uterine cavity to obtain as much tissue as possible. It is thought that this method 
collects mostly the functional layer of endometrium. The contents of the pipelle 
sampler were utilised for RNA extraction, histochemical analysis and cell culture. 
 
 
 
 
3.2.5: Biopsy storage 
For each participant, three samples were collected and stored differently, depending 
upon the intended purpose of that given sample. For example, for tissue culture, 
tissue was immediately transferred to a sterile universal containing 15ml of 
Figure 3.5: Pipelle. The Pipelle endometrial sampler was used to isolate 
endometrium from women not undergoing a hysterectomy. 
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collection medium (section 3.4.7 for media details) and placed on ice. Samples were 
stored at +4°C and prepped within 24 hours to increase cell yield and viability. 
 
To prevent RNA degradation, tissue was immediately transferred to a cryovial 
containing 500µl of RNAlater® (Applied Biosciences, Warrington, UK). 
RNAlater® is a solution that aims to stabilise cellular RNA in unfrozen tissue 
samples before being stored at -80°C.  
 
In order to prevent decay, putrefaction and autolysis of the dead tissue, tissue was 
directly transferred to a universal containing 10% neutral buffered formalin (NBF; 
Sigma-Aldrich, Poole, UK) for histochemical analysis. 
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3.3. Immuno-histochemistry 
3.3.1: Fixation 
Samples were fixed in the standard fixative 10% NBF (Sigma-Aldrich). NBF is 
thought to form cross-links with proteins and aldehydes within the cells, creating a 
gel-like substance. This enables the sample to retain its cellular constituents in vivo, 
yet also withstand the subsequent events of staining. The dimensions of all samples 
were small enough to enable sufficient penetration between 1 and 3 days in NBF at 
room temperature.  
 
3.3.2: Processing 
Tissues were processed via the use of an automated processing machine using 
standard protocol (Shandon Citadel 1000 Processor, Cheshire, UK). Tissue 
processing aims to dehydrate the sample and impregnates it with a solidifying 
medium, permitting the cutting of very thin sections. In this case, the replacement 
medium was paraffin wax (Histoplast PE, Thermo Scientific, Loughborough, UK). 
See Table 3.1 for the automated schedule of processing fixed endometrial samples.  
 
3.3.3: Embedding 
Tissue was embedded with paraffin wax using the Shandon Histocentre 3 
Embedding Station. Paraffin embedding was preferred to frozen samples as tissue 
architecture and cell morphology is better retained. For further details, see 
“Embedding Samples” in Appendix II. 
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3.3.4: Transferral of sample to slide 
Consecutive sections were cut at 3µm thickness using Microm rotary microtome 
(Microm Ltd., London, UK) and were floated out onto a pre-warmed water bath at 
40°C, until any creases in the paraffin had flattened out. Slides, which had already 
been coated with aminopropyl triethoxy saline (APES), were used to pick up floating 
sections and left to dry overnight at room temperature. For more details on APES 
coating of slides see “APES coating slides” in Appendix II.  
 
 
Step	   Solution	   Time	  
1	   4% NBF	   45 minutes	  
2	   60% Ethanol	   1 hour	  
3	   70% Ethanol	   1 hour	  
4	   90% Ethanol	   1 hour	  
5	   100% Ethanol	   1 hour	  
6	   100% Ethanol	   1 ½ hours	  
7	   100% Ethanol	   2 hours	  
8	   Xylene 1	   1 hour	  
9	   Xylene 2	   1 ½ hours	  
10	   Xylene 3	   2 hours	  
11	   Wax 1	   2 ½ hours	  
12	   Wax 2	   3 ½ hours	  
Table 3.1: Automated schedule of processing 
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Table 3.2: Reagent incubation times for de-waxing of slides 
3.3.5: Preparation of the slide 
Before any form of staining took place, the slide was baked at 60°C for one hour or 
alternatively at 37°C overnight. This was to ensure the sample was fully adhered to 
the glass slide. However, care was taken to prevent ‘over-baking’, which would 
increase background staining when performing immuno-histochemical reactions. 
Once on the slide, samples needed to be removed of wax to allow sufficient 
penetration of the aqueous stain, whether chemical of immuno-reactive. Slides were 
de-waxed using a standard protocol. See Table 3.2 for reagents and incubation times. 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.6: Antigen retrieval methods 
The formation of cross-links during formalin fixation can mask antigen epitope sites, 
and reduce the affinity for the corresponding antibody paratope. For this reason, heat 
induced epitope retrieval was used as a pre-treatment to improve results. 
Accordingly, slides were added to boiling buffer in a stainless steel pressure cooker. 
Step Solution Incubation Time 
1 Xylene 10 minutes 
2 Xylene 10 minutes 
3 100% Ethanol 5 minutes 
4 100% Ethanol 5 minutes 
5 90% Ethanol 1 minute 
6 70% Ethanol 1 minute 
7 Water  
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After 1 minute, the slides were rapidly cooled and washed in Tris-buffered saline 
(TBS) in preparation for standard immuno-histochemistry. Citrate 10mM (pH6.0) 
and Tris-EDTA (pH9.0) were the only buffers used. For details as to which buffer 
was used for each antibody see Table 3.4. 
 
3.3.7: Standard immuno-histochemistry protocol 
Immuno-histochemistry is a standard procedure that is commonly used to identify 
cell phenotypes based on a variety of markers. The concept relies on the ‘lock and 
key’ analogy of a specific antigen and antibody. In order to discuss the concept of 
immunohistochemistry, it is necessary to first consider the antibody. Antibodies are a 
group of proteins, also called immuno-globulins (Ig). They recognise a unique part of 
a foreign target/antigen (e.g. SSEA-1) and are made of basic structural units, 
including 2 heavy chains and 2 light chains to produce a Y shaped structure. There 
are five types of heavy chains: α, δ, ε, γ and µ. They are classified as IgA, IgD, IgE, 
IgG and IgM on account of which heavy chain the Ig possesses. Each tip of the Y 
shaped structure contains a paratope that is specific for one particular epitope on an 
antigen. This key and lock analogy allows structures to bind together with high 
specificity. 
 
In this study the two-step polymer-based approach was used. The method involves 
the addition of a primary antibody to a complementary antigen on the cell surface 
(Figure 3.6) The second step requires the use of a secondary antibody conjugated to 
an enzyme polymer, in this case Horse Radish Peroxidase (HRP). When the substrate 
3’3-Diaminobenzidine (DAB) is finally added, the HRP enzyme produces an 
insoluble brown precipitate making it visible on the slide.  
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Since this method requires use of HRP, pre-treatment with 0.3%H2O2/TBS (Sigma-
Aldrich) for 10 minutes at room temperature was required to quench endogenous 
peroxidase activity. Slides were then washed in TBS before being marked with a 
hydrophobic pen, ensuring all tissue was surrounded with enough space to allow the 
antibody to spread. Slides were washed a second time in TBS and then incubated in 
horse serum block for 20 minutes (Vector Laboratories, Peterborough, UK) at room 
temperature to minimise background staining (if required). For details as to which 
antibody was blocked see Table 3.3. 
 
Sections were then incubated with the primary antibody in a humidified chamber (for 
concentrations, incubation periods and temperature see Table 3.3). After incubation, 
slides were washed twice in TBS for 5 minutes and the polymer (ImmPACT kits, 
Vector Laboratories) from the same host was added for 30 minutes at room 
temperature. Once the polymer was removed; the slides were washed twice more in 
TBS for 5 minutes and the DAB substrate (ImmPACT, Vector Laboratories) was 
Step One 
Primary 
Antibody 
Antigen 
Step Three 
+ DAB 
substrate 
Insoluble 
Chromogen 
Secondary 
Antibody 
Antigen 
Primary 
Antibody 
Step Two 
Polymer 
Enzyme 
Secondary 
Antibody 
Primary 
Antibody 
Antigen 
Figure 3.6: Immuno-histochemistry. A primary antibody is first applied, 
complementary to the antigen of choice. A secondary antibody conjugated to an 
enzyme polymer in then applied. When DAB substrate is finally added, the enzyme 
produces an insoluble brown precipitate. 
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added and left to incubate at room temperature in a humidified chamber. The 
reaction was stopped after 10 minutes by immersing the slides in H20. 
3.3.8: Antibodies 
Table 3.3: Antibodies, concentrations, incubation times and supplier details  
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3.3.9: Controls 
In order to establish whether the experiment had been successful, a positive control 
was used for each antibody. Likewise, a negative control was incorporated into each 
run to verify that the staining was specific. In this case, an IgG from the same host 
species at the same concentration was used.  
 
Antibody Antigen 
Retrieval 
Positive Control tissue Anticipated Marker 
ER-  Citric acid Breast cancer Oestrogen dependency 
ER-  Citric acid Secretory endometrium Oestrogen dependency 
PR Citric acid Proliferative endometrium Progesterone dependency 
CK18 Citric acid Endometrium Urogenital epithelia 
 -Catenin Citric acid Endometrium Epithelia 
panActin Citric acid Endometrium Polarity (apical) 
NANOG Citric acid Endometrial carcinoma Undifferentiated state 
OCT4a Citric acid Endometrial carcinoma Undifferentiated state 
SOX2 Citric acid Endometrial carcinoma Undifferentiated state 
PODXL Citric acid Kidney Undifferentiated state 
SSEA-1 Tris/EDTA Kidney Undifferentiated state 
CK5/6 Tris/EDTA Breast Undifferentiated state 
H2AX Citric acid Skin DNA damage 
8-OHdG Citric acid Colorectal carcinoma Oxidative stress 
Telomerase Citric acid Tonsil Prolonged self-renewal 
Ki67 Citric acid Tonsil Proliferation 
M30 Citric acid Colorectal carcinoma Apoptosis 
CPP32 Citric acid Tonsil Apoptosis 
Table 3.4: Antigen retrieval methods, positive controls and anticipated marker 
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3.3.10: Haematoxylin staining 
Sections were counterstained with haematoxylin to allow for full histological 
analysis. Haematoxylin is a basophilic nuclear stain that is blue/black in colour. Once 
oxidised, it forms haematein and has a high affinity to nuclear acids within the 
nucleus. Slides were dipped into Gills 2 haematoxylin (Thermo Scientific) for 1 
second and then rapidly transferred to H20. They were then de-hydrated using 
standard methods and mounted with consul-mount (Thermo Scientific). In addition, 
all patient samples used in the study routinely underwent haematoxylin and eosin 
(H&E) staining to establish cycle stage (for more details see Appendix II). 
 
3.3.11: Dating of the biopsy 
Despite the LMP being recorded from each participant, the possibility of recall bias 
and cycle irregularity meant that this method was ill equipped at accurately 
predicting cycle stage. An alternative method was used, which required routine 
histological analysis. Samples were dated in accordance with Noyes criteria and 
assessed independently by a blinded consultant gynaecologist and a gynaecological 
pathologist.194 Those biopsies in perfect agreement between the two were used for 
the study.  
 
3.3.12: Image analysis 
Microscope slides were visualised and captured using Nikon Biophot Microscope 
and camera head (Nikon, Tokyo, Japan). Images were analysed using ImageJ 
software (version 1.46). Positive cells were counted and given as a proportion of 
total cells in polarised glands-like structures, generated from 3D culture. 10 in vivo 
glands from each of the following categories were analysed in the same way; pre-
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menopausal functional and basal eutopic endometrium at the WOI from patients with 
and without endometriosis, and PM endometrium. The basal layer of the 
endometrium was defined as 300µm above the endo-myometrial interface and the 
functional layer was the area from the epithelial surface to the basal layer.60  
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3.4 Cell Culture 
3.4.1: Epithelial cell isolation 
As discussed previously the endometrium is comprised of epithelia and stroma. 
Separation of these cell types was achieved by mechanical and enzymatic digestion. 
Under culture conditions, stromal cells are bipolar and have an elongated shape. 
Epithelial cells are more polygonal in appearance and grow in discrete patches 
(Figure 3.7). 
 
 
 
 
 
 
This separation technique relies largely on two principles;  1. After mechanical/enzymatic digestion, epithelia exist in clusters due to their 
stronger cell-cell junctional bonds, whereas stromal cells can easily be 
separated into single cells. 	  
2. Stromal cells adhere to plastic surfaces more readily than the epithelial cells 
and survive in isolation.	  
Based on these principles when filtrated, stroma pass through and epithelia are 
retained (Figure 3.8). The fractions are further enriched by selective adherence. 
 
 
a b 
a 
Figure 3.7: Endometrial cells in culture; Epithelia (a); Stroma (b)  
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In order to obtain the epithelial fraction, the biopsy was first transferred to a petri-
dish. Two scalpel blades (size 22, Swann-Mortem) were used in a criss-cross manner 
to chop the sample until it resembled the consistency of a fine mince. The tissue 
fragment suspension was then transferred to a 30ml universal tube and centrifuged 
for 5 minutes at 500g at 4°C. The pellet was re-suspended in 4ml of DMEM (Sigma-
Aldrich) and incubated with 100µl DNase 1, 4mg/ml, (Roche) 500µl collagenase, 
20mg/ml, (Invitrogen, Paisley, UK) and 500µl dispase, 10mg/ml, (Invitrogen) in a 
shaking water-bath for 90 minutes at 37°C. Afterwards, the cell suspension was 
filtered through a 40µm cell strainer (VWR Jencons, Leicestershire, UK) into a 50ml 
tube. The flow through solution was presumed to be the stroma and discarded. The 
cell strainer was then backwashed with more DMEM into a second 50ml tube 
(VWR). The backwash retentate was believed to be enriched with epithelia and then 
spun at 500g for 5 minutes at 4°C.  
 
Clustered epithelial 
cells do not pass 
through 
Cell strainer is 
reversed and 
rinsed 
Epithelial cells 
form the 
majority of the 
‘Retentate’ 
solution 
40µm cell strainer 
Stromal cells pass into 
the ‘Flow through’ 
solution 
Figure 3.8: Separation of endometrial epithelia and stroma. After mechanical 
and enzymatic digestion, cells are filtered through a 40µm strainer; stromal cells 
pass through whereas epithelial cells remain clustered and are retained.  
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Glandular epithelia occur in clusters; the initial step of enzymatic digestion fails to 
separate the epithelia into single cells. In order to generate a single cells suspension, 
the cell pellet was re-suspended in 1ml of DMEM and an equal volume of 0.25% 
trypsin/EDTA (Sigma-Aldrich) was added plus 100µl DNase 1, 4mg/ml (Roche). 
The suspension was incubated for 20 minutes at 37°C. Afterwards, the trypsin 
reaction was stopped with DMEM and centrifuged for 5 minutes at 500g. The pellet 
was finally re-suspended and plated in a 100mm dish, in a humidified incubator for 
20 minutes to enable selective adherence.  
 
To prevent stromal contamination, the principle of selective adherence was applied. 
Due to the adhesive nature of stroma, most contaminating cells stick down to the 
surface of the dish quickly. After twenty minutes the media was removed from the 
dish and transferred to a new 100mm dish. New media was added to the already 
adherent culture. A judgement was made whether the first/second plate had a higher 
population of epithelial cells with fewer stromal contamination based on 
morphological appearance.  
 
3.4.2: Magnetic cell sorting on SSEA-1 
SSEA-1 is cell surface glycan. For this reason, cells expressing this marker can be 
isolated from a cell suspension via MACS. Before discussing the methodology it is 
important to appreciate the mechanism behind the technique. MACS relies on three 
components; microbeads, a separator and a column. Microbeads are super-magnetic 
particles, roughly 50nm in diameter. In this study, direct magnetic labelling was 
used; an antibody was directly attached to a magnetic microbead. Because 
microbeads are composed of iron oxide and polysaccharides, they are bio-degradable 
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and disappear from cells within a few days: they have minimal effect on cellular 
structure, function or activity. 
 
Once incubated together, antibody specific magnetic beads bind to appropriate cells.  
The separator is a strong permanent magnet and induces a high gradient magnetic 
field upon the MACS column. When the cells are passed through the column, 
magnetically labelled cells are retained; unlabelled cells pass through. 
 
 
 
 
 
 
 
 
 
When the column is removed from the magnet, the magnetic field is lost. With 
pressure, the labelled cells pass through and can be collected. In this study both 
labelled and unlabelled cells were utilised. The advantage of MACS over other cell 
selection methods is the limited time-frame the cells are in suspension and 
consequently increased cell viability and yield.  
 
Magnetic labelling 
with anti SSEA-1 
microbeads 
Flow-through 
containing SSEA-1 
depleted cell population 
Eluate containing 
SSEA-1 enriched 
cell population 
N S 
Figure 3.9: MACS on SSEA-1  
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Cells were sorted between four and seven days after sample collection. Data from 
our laboratory (not shown) has shown that SSEA-1 expression peaks at this point. 
Media was first aspirated and cells were washed in sterile phospho-buffered saline 
(PBS; Sigma-Aldrich). 0.25% of trypsin/EDTA (Sigma-Aldrich) was added and cells 
were incubated for 5 minutes at 37°C in a humidified incubator. To stop the trypsin 
reaction, an equal volume of epithelial media was added (for list of media reagents 
see section 3.3.7). Cells were filtered through a pre-separation filter (Miltenyi Biotec, 
Surrey, U.K.) into a 50ml tube to remove any clusters of cells, which may block the 
column.  
 
The flow through was centrifuged at 500g for 5 minutes. Once centrifuged, the pellet 
was re-suspended in 1ml of MACS buffer and transferred to a microfuge tube (for 
full details on MACS buffer reagents, see 3.3.8). This was then spun for 3 minutes at 
700g. The pellet was re-suspended in 80µl of buffer and 20µl of anti-SSEA-1 
microbeads (Miltenyi Biotec) and incubated for 30 minutes at 4°C. 1ml of buffer was 
then added to the suspension and spun at 700g for 5 minutes. The pellet was washed 
in  MACS buffer again before finally being suspended in 0.5ml of MACS buffer.   
 
The column (Miltenyi) was first prepared by filtering through 0.5ml of MACS 
buffer. The loading sample was filtered and collected into a microfuge tube and 
placed on ice. The filter was washed twice more with 0.5ml of MACS buffer to 
remove and collect anymore SSEA-1- cells until a third wash was performed and 
discarded. The column was removed from the magnet and 1.5ml of epithelial media 
was added and forced with a plunger through the column. This was the eluate: 
enriched in SSEA-1+ cells. Both fractions were then counted using a Neubaur 
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Haemocytometer (CamLab Ltd., Cambridge, U.K.) and seeded at a density of 20,000 
cells/cm2 into 24 well plates (VWR) and 8 well chamber slides (BD Biosciences, 
Oxford, UK). 
 
3.4.3: Multi-lineage differentiation 
3.4.3i: Adipogenic assay 
The formation of adipocytes from MSCs is a complex process. The first phase, 
known as determination involves the commitment of a MSC to a ‘pre-adipocyte’. A 
pre-adipocyte is indistinguishable from its precursor cell, but it has lost its ability to 
differentiate into other cell types. The second phase, known as terminal 
differentiation, involves the accumulation of the typical ‘fat cell’ appearance.195 This 
involves the conversion of the fibroblast to a spherical shape. The progression is 
completed when the cells gain insulin sensitivity and the ability to synthesise and 
transport lipids. The cells accumulate lipid vacuoles that can be stained positive by 
Oil Red O. Adipocytic markers include peroxisome proliferation-activated receptor 
gamma2 (PPARγ2), said to be the ‘master of adipogenesis’.195 The CCAAT-
enhancer binding proteins (C/EBP) are also integral to development. Lipoprotein 
(LPL) is an early marker of differentiation; whereas adipocyte protein 2 (aP2) and 
adiponectin are expressed during the latter stages. Adipogenesis requires certain 
reagents, namely dexamethasone, 3-isobutyl-1-methyl-xanthine (IBMX), 
indomethacin and insulin. Dexamethasone is a glucocorticoid and induces expression 
of C/EBP and PPARγ. IBMX aims to amplify the effects of dexamethasone and 
prevents osteogenic differentiation. Indomethacin has a similar function and insulin 
appears to be the most potent ‘adipogenic-inducer’ by increasing triglyceride 
formation.196 
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Accordingly, confluent cells were stimulated with adipogenic media every 2-3 days 
(for full details on adipogenic media, see section 3.3.7). Non-stimulated cells were 
cultured in epithelial media and served as a negative control. After two weeks, cells 
were washed twice with PBS and fixed by incubation with 4% para-formaldehyde 
(PFA; Sigma-Aldrich) for 10 minutes for staining analysis. 
 
Oil Red O staining was used to confirm the presence of lipid vacuoles. Briefly, PBS 
was removed from fixed cells and replaced with 60% Isopropanol (Sigma-Aldrich). 
After 10 minutes, 60% Oil Red O stain solution was added and left for another 10 
minutes until washed with water (for full details on Oil Red O solution see section 
3.3.8). Cells were counterstained with Gills 2 haematoxylin (Thermo Scientific). 
Images were visualised and captured with the use of a Nikon Biophot Microscope 
and camera head (Nikon). 
 
3.4.3ii: Osteogenic assay 
The determination of osteoblastic lineage is also two-fold and reliant upon hormones 
and transcription factors.197 Initially the expression of Runt- related transcription 
factor-2 (Runx-2) directs a mesenchymal stem cell into osteoblastic lineage. This is 
assisted by the effect of dexamethasone, which is also instrumental at collagen 
expression in the ECM. Care needs to be taken when using dexamethasone as high 
concentrations can induce osteoporosis in vivo. β-catenin molecules and Osterix 
(OSX) allow for the further development into an immature osteoblast. Cells become 
less spindle-like and the ECM becomes mineralised with the addition of calcium and 
phosphate ions. β-glycerophosphate (β-GP) acts as a source of these ions and 
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alkaline phosphatase (ALP) expression increases to free inorganic phosphate. Early 
markers of osteoblastic differentiation comprise ALP and osteonectin. Osteocalcin 
(OC) and osteopontin (OP) are expressed later in the differentiation process.  
 
Near confluent cells were stimulated every 2- 3 days with osteogenic media for two 
weeks (for media details, see 3.3.7). Cells were stimulated with epithelial media for 
the same period and served as a negative control. On day 15, cells were fixed by 
incubation with 4% PFA at room temperature for 10 minutes and subject to analysis. 
Visual analysis consisted of ALP staining. Accordingly, PBS was aspirated from 
fixed cells and replaced with 400µl of Fast Red/Napthol solution. (Sigma-Aldrich) 
and left to incubate at room temperature. After 30 minutes, cells were rinsed with 
0.1MTris HCl (pH 9.2) and PBS before being counterstained with 4',6-diamidino-2-
phenylindole (DAPI). 
  
3.4.4: hMSC cell culture 
Human mesenchymal stem cells (hMSCs) were used as the positive control for in 
vitro differentiation into adipocytes and osteocytes (Lonza, Walkersville, Inc., USA).  
 
3.4.4i: Cell thawing protocol 
hMSC were thawed by removing cell containing cyrovials from a liquid nitrogen 
tank. The cryovial was promptly transferred to a waterbath at 37°C. As soon as the 
cell suspension thawed, it was transferred to a 15ml tube, pre-filled with warmed 
hMSC Growth MediumTM (hMSCGM; Lonza, Walkersville Inc., USA). 
Subsequently, the cells were centrifuged at 300g for 3.5 minutes and the supernatant 
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discarded. The cell pellet was re-suspended in hMSCGM and transferred to a dish, 
before being placed in a humidified incubator at 37°C, 5% CO2 in air. 
 
3.4.4ii: Cell passaging 
In order to passage cells, culture medium was aspirated. The cells were washed twice 
in sterile PBS. Next, cells were incubated with 0.25% trypsin/EDTA (Sigma-
Aldrich) for 2 minutes in a humidified incubator. The trypsin reaction was then 
stopped with an equal volume of pre-warmed hMSCGM (Lonza). The cell 
suspension was transferred to a 15ml tube and spun at 300g for 2.5minutes. Cells 
were re-suspended in 1ml hMSCGM before being counted using a Neubauer 
Haemocytomer (CamLab). Usually cells were passaged in a 1 to 2 ratio and were 
expanded up to passage 7. 
 
3.4.4iii: Routine hMSC culture 
Cells were cultured according to manufacturer’s instructions. Briefly, hMSCs were 
maintained in hMSCGM on uncoated dishes. Media was changed every 2-3 days. 
Cells were passaged when they reached 90% confluency, roughly every week. Cells 
were seeded according to manufacturer’s instructions at 5,000-6,000 cells per cm2 of 
surface area. 
 
3.4.5: Pluripotency assay (Neurogenic trans-differentiation) 
Cells were plated onto pre-coated MatrigelTM chamber slides to increase cell 
viability. Once cells had reached near confluence, epithelial media was aspirated and 
replaced with neurogenic media, kindly donated by Dr. D Wilkinson, University of 
Liverpool.  Media was changed every 3-4 days.  
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After 10 days cells were fixed with 4% PFA and subjected to immuno-fluorescence 
using a standard technique. Cells were initially permeabilized with 0.1% (v/v) Triton 
X-100/PBS (VWR) for 10 minutes at room temperature. After 3 washes with PBS, 
cells were blocked with 1% (v/v) BSA/10%normal goat serum/PBS for 1 hour at 
room temperature, prior to overnight incubation with rabbit anti-protein gene product 
9.5 antibody (PGP9.5; AbD Serotec, Product Number 7863-0504, Oxfordshire, UK), 
at a concentration of 1:1000. The primary antibody was subsequently washed off and 
cells were incubated with fluorescein isothiocyanate (FITC)- conjugated anti-rabbit 
antibody (Cell Signalling) for 1 hour at room temperature before being rinsed with 
PBS. 
 
3.4.6: 3D cell culture 
3D culture required the use of MatrigelTM (BD Biosciences). SSEA-1 enriched 
fractions have been found to have a greater propensity to produce organoid/gland-
like structures than SSEA-1 depleted counterparts (1.4.7). However, a real difficulty 
is the small yield that is generated, due to prolonged culture and sorting. For this 
reason, crude epithelial cells were used in this assay, as it is presumed the structures 
will be from SSEA-1 origin.  
 
3.4.6i 3D culture of endometrial epithelial cells 
Following epithelial isolation (Section 3.3.1i) cells were cultured until confluency. 
At this point, cells were trypsinised and centrifuged at 5g for 5 minutes. The pellet 
was re-suspended in 1ml of serum free media (for media details see 3.4.7) and 
transferred to a microfuge tube. The pellet was spun once more at 700g for 5 minutes 
and re-suspended in MatrigelTM at a concentration of 5x103 cells/ undiluted 1ml 
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MatrigelTM. All work was done on ice. 50µl of cell-MatrigelTM suspension was 
placed in the centre of a 24-well-plate well and incubated at 37ºC. MatrigelTM 
hemispheres set after 20 minutes and 500µl of serum free media (see section 3.3.8 
for details) was added. Media was changed every 2 – 3 days. 
 
3.4.6ii: Harvesting 
MatrigelTM hemispheres were harvested after 10-14 days dependent upon cell 
growth. 3D cultures were fixed in 10% NBF (Sigma-Aldrich) for 30 minutes, 
harvested into 1% (w/v) agarose/PBS and placed in NBF overnight at 4°C. 3D 
cultures were processed and sectioned as previously described (section 3.3.2 
onwards). 
 
3.4.7: Culture media reagents 
Media was prepared in a sterile manner, and filtered using a 22µm filter.  
 
Collection media 
• DMEM (Sigma-Aldrich) 
• 1% (v/v) Foetal Bovine Serum (FBS; BioSera Ltd, Sussex, UK) 
• 0.2% (v/v) Primocin (Bioscience Lifesciences, Nottingham, UK) 
 
Epithelial media 
• High glucose DMEM/F12 (Lonza) 
• 2% (v/v) L-glutamine (Sigma-Aldrich) 
• 0.2% (v/v) Primocin (Sigma-Aldrich) 
• 10% (v/v) FBS (Biosera) 
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• 200ng/ml recombinant human epithelial growth factor (EGF; Sigma-Aldrich) 
 
Adipogenic media (Gargett et al., 2009)143 
• High glucose DMEM/F12 (Lonza) 
• 0.2% Primocin (Bioscience Lifesciences) 
• 500µM IBMX (Sigma-Aldrich) 
• 1µM Dexamethasone (Sigma-Aldrich) 
• 10µM Insulin (Sigma-Aldrich) 
• 200µM Indomethacin (Sigma-Aldrich) 
 
Adipogenic media  
• High glucose DMEM/F12 (Lonza) 
• 0.2% Primocin (Bioscience Lifesciences) 
• 500µM IBMX (Sigma-Aldrich) 
• 1µM Dexamethasone (Sigma-Aldrich) 
• 10µM Insulin (Sigma-Aldrich)	  
 
Osteogenic media (Gargett et al., 2009)143 
• High glucose DMEM/F12 (Lonza) 
• 0.01µM Vitamin D3 (Sigma-Aldrich) 
• 50µM L-ascorbic acid (Sigma-Aldrich) 
• 10mM β-glycerol phosphate (Sigma-Aldrich) 
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Neurogenic media (Almond et al.,  2007)198 
• Low Glucose (1mg/ml) DMEM (Invitrogen) 
• 1% (v/v) FBS (Gibco, Paisley, UK) 
• 1% N1 Supplement (Sigma-Aldrich) 
• 2mM L-glutamine (Gibco) 
• 2% (v/v) Chick embryo extract (Centrifuge 8000rpm & used 
supernatant)(Sera Laboratories Int., Horsted Keynes, UK) 
• 20ng/ml Fibroblast Growth Factor 2 (FGF2; Sigma-Aldrich) 
• 0.5mM Mercaptoethanol (Sigma-Aldrich) 
• 20ng.ml EGF (Sigma-Aldrich) 
• 100U/ml Penicillin (Gibco) 
• 100μg/ml Streptomycin (Gibco)	  
 
Serum-free media 
• DMEM/F12 (Lonza)	  
• Insulin-transferrin-selenite (ITS; Invitrogen)	  
• 50ng/ml human recombinant EGF (Sigma-Aldrich)	  
 
3.4.8: Buffers and solutions 
MACS buffer 
• Culture grade PBS (Ca2+/Mg2+ free) (Sigma-Aldrich) 
• 5% (v/v) FCS (Sigma-Aldrich) 
• 2% (v/v) EDTANa2 (VWR, Leicestershire, UK) 
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• Final solution was filtered through a 22µm mesh. 
 
4% (w/v) Paraformaldehyde 
• 4g Paraformaldehyde (Sigma-Aldrich) 
• 100ml PBS (Sigma-Aldrich) 
 
0.5% (w/v) Oil Red O solution 
• 0.5g Oil Red O (Sigma-Aldrich) 
• 100ml Isopropanol (Sigma-Aldrich) 
• Prior to use the working solution was diluted in a 3:2 ratio with H20 and 
filtered using Whatman paper 
 
Fast Red/Napthol 
• 2mg Napthol AS-MX phosphate (Sigma-Aldrich) 
• 10mg Fast Red TR (Sigma-Aldrich) 
• 10ml 0.1 TrisHCl (pH 9.2) 
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3.5: Molecular Biology 
3.5.1: RNA extraction 
Total RNA was extracted using TRIzol® reagent (Invitrogen) according to 
manufacturer’s instructions. Briefly, culture medium was aspirated and cells were 
washed with PBS. PBS was then discarded and 250µl of TRIzol® was added to each 
well (in a 24 well plate). The solution was triturated with a pipette to produce a 
homogenous solution. Technical replicates were pooled to increase total RNA yield 
and transferred into a 1.5ml microfuge tube. A fifth of the total TRIzol® volume of 
chloroform (Sigma-Aldrich) was then added. Suspensions were shaken for 15 
seconds and subsequently transferred to a centrifuge, spun at 12,000g for 15 minutes 
at 4°C. Following centrifugation, three distinct phases formed: a lower pink phase 
(containing mainly protein), a white interphase (containing DNA), and a clear 
aqueous upper phase containing the RNA. As much of the clear aqueous phase as 
possible was removed, taking care not to contaminate the sample with protein or 
DNA and each transferred to new microfuge containing 1µl of glycogen 
(Invitrogen). Half the original TRIzol® volume of Isopropanol (Sigma-Aldrich) was 
added and the solutions were inverted and left to incubate overnight at -20°C. 
Following incubation, solutions were centrifuged at 12,000g for 10 minutes at 4°C 
and the supernatant discarded. The pellet was washed in 75% EtOH (Sigma-Aldrich) 
and centrifuged for one last time at 12,000g for 8 minutes at 4°C. The supernatant 
was discarded and the pellet was allowed to air dry at room temperature. The pellet 
was then dissolved in 10-15µl of nuclease free water (Sigma-Aldrich), depending 
upon pellet size and stored at -80°C. 
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3.5.2: RNA quantification 
The quantity and purity of total RNA was assed using NanoDropTM ND-1000 
spectrophotometer (Thermo Fisher), according to manufacturer’s instructions. The 
260/280nm absorbance ratio, reflecting RNA purity, and concentration was recorded 
for each sample. Unfortunately, due to cell death and the small number of cells 
cultured, RNA quality and concentration were poor for some of the samples. Only 
the biological samples with the ‘best full set’ of RNA were used for quantitative 
polymerase chain reaction (qPCR). These were the samples with the highest 
concentration and a 260/280 value close to 2. 
 
3.5.3: DNase treatment of total RNA 
In order to prevent contamination of genomic DNA, treatment with 
deoxyribonuclease (DNase) enzymes was performed. 8µl of RNA was transferred to 
a 0.2ml microfuge tube and mixed with lµl of DNase buffer (Promega, Southampton, 
UK) and 1µl of DNase (Promega), and incubated at 37°C. After 30 minutes, 1µl of 
STOP buffer (Promega) was added and incubated at 60°C for 15 minutes. Samples 
were stored at -20°C. 
 
3.5.4: cDNA synthesis 
Complimentary DNA (cDNA) was acquired using the Superscript First-Strand 
Synthesis System. 4µl of DNase treated RNA were transferred to a 0.2ml microfuge 
tube along with 1µl of 100ng/µg stock solution of random hexamers (ABgene, 
Loughborough, UK), 1µl of 10mM dNTP mix (Bioline Ltd., London, UK) and 8µl of 
nuclease free water (Sigma-Aldrich). The solution was incubated at 65°C for 5 
minutes and then placed on ice for 5 minutes. 4µl of 5X First-Strand buffer 
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(Invitrogen), 1µl of 0.1M DTT (Invitrogen) and 1µl of Superscript III (200U/µl; 
Invitrogen) were added, and the mixture was left to stand for 5 minutes at room 
temperature. Following this, the mixture was incubated for 60 minutes at 50°C, then 
inactivated at 70°C for 15 minutes.  
 
3.5.5: Standard qPCR protocol  
qPCR enables both detection and quantification of specific cDNA. It follows the 
principle of traditional PCR: the exponential amplification of cDNA due to thermal 
cycling. However, unlike conventional PCR, in qPCR the amplified product is 
measured throughout the experiment – not at the end point. Amplified DNA is 
detected via fluorescence; the earlier the fluorescence is detected, the greater the 
number of the product. In this study, the nonspecific SYBR® Green I dye was used, 
which becomes fluorescent once upon binding to double stranded DNA (dsDNA) 
(Figure 3.10). 
 
 
 
 
 
Before preparing the qPCR reactions, cDNA samples were diluted between two and 
three fold depending upon RNA concentration. The reaction was as follows; 10µl 
SYBR® Green JumpstartTM Taq ReadyMixTM (Sigma-Aldrich), 7µl nuclease-free 
water (Sigma-Aldrich), 1µl cDNA and 1µl each of 0.25µM sense and anti-sense 
Figure 3.10: DNA-binding SYBR® Green I in qPCR. As amplification occurs, 
more dsDNA is available for SYBR® Green I to bind to. Bound SYBR® Green I is 
fluorescent; (B) bound SYBR; (U) unbound SYBR. 
U 
B 
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primers (all purchased from Sigma-Aldrich). The reaction was carried out on the 
Rota Gene RG-300 real time cycler (Corbett, Sussex, UK) and required a 10 minute 
hold period, followed by 40 cycles of 95°C for 6 seconds, 60°C for 30 seconds and 
72°C for 30 seconds. All primers had an annealing temperature of 60°C. Three 
technical replicates were run for each template and primer set. No cDNA template 
controls were included in all runs to ensure there was no contamination. A positive 
control was included to ensure the primer set was working successfully and 
calibrator samples were also included in each run to account for any inter-run 
variation. All gene expression was normalised to the endogenous reference gene 
YWHAZ, which is a protein implicated in general signalling pathways and is high in 
all cells.  
 
Following each qPCR run, a melting curve was performed to ensure amplicons were 
the same for all biological and technical replicates. The temperature was set to 
increase 1°C every 5 seconds, from 75°C to 98°C. Peaks were representative of the 
temperature the dsDNA is dissociated. Amplicons of the same size and nucleotide 
composition demonstrate a common peak (Figure 3.11). 
 
 
 
 
 
 
 
Figure 3.11: Melt curve of amplicons. Different coloured peaks represent 3 different 
amplicon products. 
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Results were collated using the Rotor Gene 3000 analysis software (version 6.1). The 
threshold was set to be both above the background fluorescence and also in the log-
linear phase of the curve (Figure 3.12). The point at which the curves crossed the 
threshold was measured and defined as the CT. CT values were normalised to the 
endogenous reference gene and analysed according to the Pffafl method using the 
REST-2009 software (version 1).199 Primer efficiency was assumed to be 1.0. 
 
 
 
 
3.5.6: Oligonucleotide primers 
All primers were reconstituted accordingly in 1ml nuclease-free water (Sigma-
Aldrich) to reach a working volume of 6.25pmol/µl. Aliquots were stored at -20°C 
until needed. The control for ADiPOQ, aP2, LPL and PPARγ2 were human mature 
adipocytes, kindly donated by Dr. C Bing, University of Liverpool. Likewise, Dr. D 
Barraclough, University of Liverpool, provided human osteoblastoma RNA as a 
control for ALP, RUNX2, OSX and OC (for full list of sequences, see Table 3.5). 
 
Figure 3.12: CT values for target and reference genes. The threshold was set to 
cross the log-linear phase of the reaction and above any background; (a) represents 
the YWHAZ CT value; (b) represents the reference gene CT value. 
a b 
Background 
Log-linear phase 
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3.5.7: Gel electrophoresis 
Gel electrophoresis was conducted using the FlashGelTM System (Lonza, Vervieres, 
Belgium) using manufacturers instructions. Briefly, 1µl of amplicon, 1µl of loading 
buffer (Lonza) and 3µl of nuclease free water (Sigma-Aldrich) was added to each 
well and run at 250V for 5 minutes. Images were captured using the FlashGelTM 
camera (Lonza). 
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Primer Sequence  Size Source 
hADiPOQ S: AGCCTCCTTCTCCTGGGTCC 
AS: GTTGCCTCTAGCCTGGTGGG 
295bp  Yang et al., 
2011200 
haP2 S: ACCAGGAAAGTGGCTGGCAT 
AS: CAGGTCAACGTCCCTTGGCT 
331bp   Yang et al., 
2011200 
hLPL S: GAGATTTCTCTGTATGGCACC 
AS: CTGCAAATGAGACACTTTCTC 
276bp  Yang et al., 
2011200 
hPPAR 2 S: TGTCTCATAATGCCATCAGGTTT 
AS: GATAACGAATGGTGATTTGTCTG 
224bp  Yang et al., 
2011200 
hALP2 S: GGACATGCAGTACGAGCTGA 
AS: CCAGCAAGAAGAAGCCTTTG 
113bp Glennon-Alty 
2012201 
hRUNX2 S: TCCTTAGAACAAATTCTGCCCTTT 
AS: TGCTTTGGTCTTGAAATCACA 
136bp Wang et al., 
2012202 
hOSX S: CCTCCTCAGCTCACCTTCTC 
AS: GTTGGGAGCCCAAATAGAAA 
148bp  Wang et al., 
2012202 
hOC S: GAAGCCCAGCGGTGCA 
AS: CACTACCTCGCTGCCCTCC 
70bp  Glennon-Alty 
2012201 
hYWHAZ S: CGTTACTTGGCTGAGGTTGCC 
AS: GTATGCTTGTTGTGACTGATCGAC 
69bp Marullo et al., 
2010203 
hACTB S: AGTGTGACGTGGCACATCCGCA 
AS: GCCAGGGCAGTGATCTCCTTCT 
112bp  Marullo et 
al., 2010203 
Table 3.5: Oligonucleotide primers. S: sense, AS: anti-sense 
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3.6: Statistical Analysis 
Statistical analysis of gene expression was performed using the REST-2009 software 
(version 1).199 Statistical analysis of neural differentiation was performed using the 
GraphPad Prims software (version 5). Since data were paired and n=3, the Wilcoxon 
test was used. P values <0.05 were considered statistically significant. Data are 
presented as mean ± SD unless otherwise specified. 
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Chapter Four:  
OPTIMISATION AND 
VALIDATION OF RESULTS 
 
In order to improve experimental outcome, a number of optimisations took place for 
each technique. Examples are covered within this chapter. 
 
4.1: Immuno-histochemistry 
Most antibodies in this project had previously been optimised; this was not the case 
for β-catenin and panActin. Control sections were incubated with antibodies at 
various concentrations. The purpose of this was to find a balance between strong 
target, and background staining. Serial dilutions of the antibody were assessed; for β-
catenin, 1:200, 1:400 and 1:800; for panActin, 1:250, 1:500, 1:1000 (Figure 4.1). 
 
There were difficulties regarding the counterstaining of organoids. Standard methods 
typically over-stain sections with haematoxylin, only to ‘de-differentiate with acid 
ethanol. The result is a clear image, one that easily enables visualisation of DAB 
products in cell structure. The acid alcohol treatment was noted to be harsh on the 
organoid sections, sometimes causing loss of the gland-like structures/organoids 
from the slides. This step was therefore omitted, necessitating a much shorter time in 
haematoxylin. The same incubation time was applied to whole tissue sections.  
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β-Catenin panActin 
1:400 
1:800 
1:1200 
1:250 
1:500 
1:1000
Figure 4.1: Optimisation for immuno-histochemistry  
Serial dilutions for the antibodies β-Catenin and panActin were performed. A 
concentration of 1:400 for β-Catenin was chosen for future experiments. Likewise, a 
concentration of 1:500 for panActin was chosen. 
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4.2 Cell Culture 
4.2.1: Multipotency 
Initially, the adipogenic differentiation protocol was taken from Gargett et al., 
2009.143 The authors had successfully differentiated human ESt-ASPC into 
adipocytes and did not complain of any difficulties. However, when this media was 
added to human endometrial epithelial cells, it quickly became apparent that the 
media was promoting cell senescence and death. Three out of four biological 
replicates underwent apoptosis within 24 hours of incubation with this media; cells in 
control media were still viable. The only sample to survive more than 24 hours had 
an unusual phenotype; ‘vacuoles’ appeared to be present within the cell structure 
(Figure 4.2). These did not stain positive with Oil Red O, and are likely to be 
representative of cell membrane rupture. Modifications were made to the media, with 
the use of more dilute reagent concentrations. Indomethacin was completely 
removed from the protocol, as a thorough literature search found this had a 
deleterious effect on human endometrial epithelial cells.204 hMSCs were seeded in 
triplicate and subjected to the same media, to validate the experiment. 
  
 
 
 
 
 
 
 
 
100µm 50µm 
a b 
* 
** 
Figure 4.2: Optimisation of cell culture 
Adipogenic induced SSEA-1 enriched and depleted fractions underwent cell death 
or produced large vacuoles (a), see *. These were negative for for Oil Red O (b), 
see **. 
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4.2.2: Pluripotency 
For neurogenic assays, cells were initially cultured in 8 well chamber slides. 
However, it quickly became apparent that cell viability was poor. This was overcome 
by two strategies; firstly the protocol was shortened from 3 weeks to 7-10 days, and 
secondly, a film of MatrigelTM was plated over the slide chamber base. 
 
4.3: Molecular Biology 
Before the commencement of qPCR reactions, reference genes were run on RNA, 
DNase-treated RNA, and cDNA for each sample set (Figure 4.3). The purpose of 
which, was to confirm genomic DNA had been degraded, and cDNA synthesis had 
been effective. DNase-treated RNA should have the highest CT value (less content); 
RNA should have a slightly lower value as it contains some genomic material. 
However, cDNA should have the lowest value and will be detected first.  
 
 
 
 
 
 
 
 
In this project, the reference gene YWHAZ was used. Before analysis of target genes 
expression, YWHAZ was compared with another reference gene, β-actin across all 
Figure 4.3: Verification of successful cDNA synthesis.  
qRT-PCR curves for DNase treated RNA (a); RNA (b); and cDNA (c) from the 
same biological sample.  
a 
b 
c 
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samples. The purpose was to confirm that YWHAZ expression was stable; the Δ-Ct 
value of the two reference genes was consistent throughout all samples, mean 4.57 ± 
0.39 (Figure 4.4). This confirms the work of others, which suggests that YWHAZ is 
more stable in human endometrium.205 
 
 
 
 
 
 
 
 
Validation of primers was assessed via base pair (bp) size of qPCR products. Gel 
electrophoresis of qPCR products from control template was performed (Figure 4.5). 
 
 
 
 
Figure 4.4: Verification YWHAZ stability 
YWHAZ (a) and β-actin (b) gene expression was analysed. The Δ-Ct value was 
calculated and was constant across all cDNA samples. 
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Figure 4.5. Verification of qPCR primers 
Products of qPCR were run on a gel to ensure band size was correct. 
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Chapter Five: RESULTS 
 
 
 
5.1: Assessment of unipotency of EEp-ASPCs in vitro 
A total of eight patient samples were cultured in 3D media to produce gland-like 
structures, median age 30.5 years (range 27 – 47 years). Reasons for surgery 
included menorrhagia (without identified endometrial pathology, such as 
inflammation or malignancy), and non-endometrial related causes, such as 
sterilisation and cystectomy. Data are incomplete for three recruited patients (for 
patient demographics see Table 5.1). Gland-like structures were subjected to 
immuno-histochemical analysis and compared to reference tissue sections from three 
patients; eutopic endometrium from a woman suffering with endometriosis, a fertile 
control and a PM sample (for demographics of reference tissue see Table 5.2). 
 
 
No Biopsy  Reason for 
Surgery 
Endometriosis Age BMI Gravida Cycle Stage 
1 FT Menorrhagia No 30 26.7 1 Proliferative 
2 FT  No 47 27.7 4 Late 
Proliferative 
3 Pipelle Laparoscopy 
Dye Test 
Yes 28 25.5 0 Mid-
Secretory 
4 Pipelle Cystectomy Yes 39 24.8 0 Late 
Proliferative 
5 Pipelle Diagnostic 
Laparoscopy 
Yes 21 18.7 1 Proliferative 
6 Pipelle  No 38 26.6 2 Menstrual 
7 Pipelle Laparoscopic 
Sterilisation 
No 27 23 5 Early 
Secretory 
8 Pipelle  No 27 21.1 4 Secretory 
1
Table 5.1: Patient demographics of samples used to assess unipotency of EEp-ASPCs 
2
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5.1.1: EEp-ASPCs are capable of producing gland-like structures in 3D culture 
After 14 days in 3D culture, all samples generated single lumen 
spheroids/organoids/gland-like structures. Two types existed; comprised of non-
polarised cells, and those comprised of polarised cells, with the former accounting 
for approximately 90%. It is the polarised structures that are the subject for much of 
this study. No difference in morphology was observed between samples taken from 
endometriosis patients and fertile controls, other than the general observation that 
endometriosis samples produced spheroids/organoids at faster rate. 3D structures 
morphologically mimicked glands present in human endometrium. Cells showed 
positive immuno-reactivity for the epithelial marker CK18, and adhesion molecule β-
catenin, confirming that cells structures were epithelial (Figure 5.1). panActin at the 
apical surface of the epithelia illustrated that cells were polarised and differentiated. 
The panActin staining pattern differed between ex vivo and in vivo glands; being 
more localised in endometrial tissue. Interestingly, one ex vivo gland demonstrated 
the classical in vivo appearance on half of the gland, whilst maintaining the ex vivo 
pattern on the other (Figure 5.1f). 
 
Reference Biopsy  Reason for Surgery Age BMI Gravida Cycle Stage 
Endometriosis FT Endometriosis 45 20.5 2 WOI 
Fertile Control FT Pelvic Pain NAD 30 28.1 3 WOI 
PM FT Prolapse 77 26.6 2 N/A 
Table 5.2: Patient demographics for samples used as reference tissue for gland-like 
structures 
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Figure 5.1.1: Endometrial SPCs are capable of producing gland-like structures in 3D culture. 
After 14 days in 3D culture, gland-like structures developed (a-f). These resembled glands formed in 
endometrial tissue sections (g-i) and stained positive for the structural proteins CK18 (a,d,g), β-Catenin 
(b,e,h) and panActin (c,f,i).  
CK18 β-Catenin panActin 
g 
Figure 5.1: EEp-ASPCs are capable of producing gland-like structures in 3D culture 
After 14 days in 3D culture, gland-like structures developed (a-f). These resembled 
glands formed in endometrial tissue sections (g-i) and stained positive for structural 
proteins CK18 (a,d,g); β-Catenin (b,e,h) and panActin (c,f,i). 
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5.1.2: Gland-like structures best resemble post-menopausal glands from 
endometrial tissue 
Polarised gland-like structures were mainly spherical or elliptical in shape and 
resembled either basal or PM endometrial glands. They did not resemble the highly 
coiled and differentiated glands of functional endometrium seen at the progesterone-
dominant WOI (Figure 5.2). Steroid receptor expression profile of the oestrogen 
receptor subtypes ER-α, ER-β and PR was compared across the five groups, and data 
demonstrated that organoids best resemble PM endometrial glands for the following 
reasons. 
• Expression of ER-α in reference glands was almost negligible in the basal 
layer, and greater in the functional layers of both groups of cycling 
endometrium. The intensity and number of positive cells was maximal in PM 
endometrium. Mean expression of ER-α in gland-like structures was 88.62 ± 
8.74% compared with 81.70 ± 10.17% in PM tissue.  
• A similar effect was observed with ER-β; more staining was visible in the 
functionalis when compared with the basal layer, and strongest in PM 
endometrium. ER-β expression was 94.47 ± 5.55% in gland-like structures 
versus 99.71 ± 0.93% in PM endometrium.  
• PR expression in reference glands was intense in both layers of all cycling 
endometrium. PR was expressed at a lower extent in PM endometrium, and 
even less so in gland-like structures; 83.79 ± 9.06% versus 31.79 ± 9.31% 
respectively. 
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Figure 5.2: Gland-like structures best resemble post-menopausal glands from 
endometrial tissue. Organoids (a-f) were compared with human pre- and post-
menopausal endometrium (g-h). ER-α, ER-β and PR was expressed in all structures. 
However, based on hormonal receptor profile, gland-like structures best resembled 
PM glands (j). 
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5.1.3: Gland-like structures demonstrate negative immuno-reactivity for ESC 
transcription factors 
Cells comprising the gland-like structures demonstrated negative immuno-reactivity 
for markers of an undifferentiated state; NANOG, OCT4a and SOX2. Some 
NANOG and OCT4a staining was observed in most cells. However, upon colour de-
convolution, it became clear the staining was not nuclear and thus considered to be 
negative (Figure 5.3). 
 
  
a b c 
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Figure 5.1.3: Gland-like structures demonstrate negative immuno-reactivity for ESC markers 
Gland-like structures showed negative immuno-reactivity for ESC markers Nanog (a); Oct4a (b); 
and Sox2 (c). Nanog and Oct4a produced some staining, however upon colour de-convolution 
(d&e respectively), staining was not nuclear. Control tissue was endometrial cancer, which had 
positive nuclear and and non-nuclear staining for Nanog (g); Oct4a (h) and Sox2 (i). 
NANOG OCT4a SOX2 
Figure 5.3: Gland-like structures demonstrate negative immuno-reactivity for 
ESC transcription factors. Gland-like structures showed negative immuno-
reactivity for undifferentiated markers NANOG (a); OCT4a (b) and SOX2 (c). 
NANOG and OCT4a produced some staini g, however, upon colour de-convolution 
(d & e respectively), staining was not nuclear. Control tissue was endometrial 
cancer, which had nuclear and non-nuclear staining for NANOG (g); OCT4a (h) and 
SOX2 (i). 
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5.1.4: Gland-like structures show positive immuno-reactivity for ASPC markers 
Gland-like structures were stained with the ASPC markers PODXL, CK5/6 and 
SSEA-1. 
• PODXL staining in reference tissue was present in vascular endothelia and 
upon the apical surface of endometrial glands. Epithelial staining was greatest 
in PM tissue. Staining of gland-like structures revealed cells had less 
immuno-reactivity for PODXL when compared to reference tissue (Figure 
5.4).  
• SSEA-1 was strongly expressed, and present on the apical surface of cells in 
all reference groups. SSEA-1 staining intensity was strongest in PM tissue 
and the basal layers of both endometriosis and fertile control endometrium. 
All cells comprising polarised gland-like structures showed strong intensity 
staining for SSEA-1 (Figure 5.4).  
• In reference tissue, CK5/6 stained epithelia only; no CK5/6+ stroma or 
endothelia were observed. Luminal epithelia were stained consistently; 
several glands were stained positive for CK5/6 (Figure 5.4). Interestingly, 
undefined structures consisting of cells that did not express CK18 were 
present in the 3D culture from patient 5, which showed strong immuno-
reactivity for CK5/6. (Figure 5.6).  
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5.1.5: Expression of markers of cell fate in gland-like structures showed that cells 
are actively proliferating 
As discussed earlier, gland-like structures were analysed for immuno-reactivity to 
markers of proliferation, senescence, and apoptosis such as Ki67, telomerase, 8-
OHdG, H2AX, M30 and CPP32 to determine cell fate. Several Ki67+ cells were 
present in each gland-like structure indicating proliferation. Organoids had a strong 
staining intensity for telomerase, suggestive of progenitor features. Senescent makers 
8-OHdG and H2AX were present in certain cells of each organoid. Unfortunately, it 
a 
d 
b c 
e f 
* 
* 
VE 
LE 
SSEA-1 PODXL CK5/6 
Figure 5.4: Gland-like structures show positive immuno-reactivity for ASPC 
markers. Gland-like structures demonstrated strong immuno-reactivity for SSEA-1 
(a), similar to glands in PM and basal tissue (d). PODXL was present on the apical 
surface of some gland-like structures, see * (b), but was considerably less intense 
than seen in tissue (e), see *, where gland and vascular endothelia were PODXL+, 
see VE. CK5/6 was not seen in gland-like structures (c), and in reference tissue (f) 
luminal epithelia were consistently stained, see LE, along with occasional whole 
glands.  
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was difficult to establish sequential sections for these antibodies. Therefore, it cannot 
be determined whether some cells had strong intensity for Ki67 yet negative for 
oxidative stress and senescent markers 8-OHdG and H2AX, which would be 
indicative of an ASPC. Nonetheless, all cells in organised structures were negative 
for apoptotic markers CPP32 and M30. A very small number of cells in non-specific 
clusters were M30+ (Figure 5. 5g).  
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Figure 5.1.5: Gland-like structures are actively proliferating. Gland-like structures demonstrated 
positive immune-reactivity for telomerase (a), H2AX (b), 8-OHdG (c) and Ki67 (d). Apoptotic 
markers M30 and CPP32 were negative in gland-like structures (e&f respectively). M30 was pre-
sent in some cells that were aggregated in loose clusters (g) but CPP32 was not (h). 
Figure 5.5: Gland-like structures are actively proliferating 
Gland-like structures demonstrated positive immuno-reactivity for telomerase (a), 
H2AX (b), 8-OHdG (c) and Ki67 (d). Apoptotic markers M30 and CPP32 were 
negative in gland-like structures (e & f respectively). M30 was present in some cells 
that were aggregated in loose clusters (g), but CPP32 was not (h). Insets represent 
controls. 
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5.1.6: 3D culture supports growth of non-gland-like structures  
3D structures generated from patient 5, harvested at day 10 and 14, produced non-
gland-like, as well as gland-like structures. Morphologically, these structures 
resembled distinct solid spheres, unlike anything observed in reference tissue. Solid 
structures appeared to comprise epithelia on the outer circumference, which stained 
positive for CK18, β-Catenin and panActin, and an inner mass, which did not 
express any of these structural proteins (Figure 5.6). The inner mass of cells was 
negative for apoptotic markers CPP32 and M30. Interestingly, these cells were also 
negative for the steroid receptors, and markers of proliferation and senescence. 
Likewise, cells were also negative for ESC makers and APSC markers PODXL and 
SSEA-1. Out of all the markers used in this study, cells comprising the inner mass 
only showed positive immuno-reactivity to CK5/6. 
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Figure 5.6: 3D culture supports growth of non-gland-like structures. Solid spheres 
formed in 3D culture that did not resemble gland-like structures. These appeared to 
consist of two cell types – an outer layer that resembled epithelia, staining positive 
for the structural proteins CK18, β-Catenin and panActin (*), and an inner mass that 
were negative (**). Inner mass cells were negative for ER-α, ER-β and PR. Cells 
also were negative for H2AX, 8-OHdG and apoptotic markers CPP32 and M30. 
Telomerase, Ki67, SSEA-1 and PODXL were negative, but interestingly, CK5/6 
was present in all cells within the inner mass.  
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5.2: Assessment of multipotency of EEp-ASPCs in vitro 
Samples from eleven patients were collected and cultured in either adipogenic or 
osteogenic media, to promote mesodermal differentiation. The median age of these 
patients was 45 (range 31 to 47 years; for patient demographics see Table 5.3). Cells 
from sample 19 did not survive in either the control or interventional media.  All 
remaining samples were stained at the end of the 14-day protocol. The 3 samples 
with the highest set of mRNA concentration and 260/280 values were assessed for 
gene expression: samples 12, 14 and 15 for the adipogenic assay and 9, 12 and 13 for 
the osteogenic assay (for mRNA concentration and 260/280 values see Table 5.4). 
hMSC were cultured in the same conditions and acted as a positive control. 
 
 
No. Biopsy Reason for 
Surgery 
Endometriosis Age BMI Gravida Cycle Stage 
9 FT Menorrhagia No 45 33.1 2 Proliferative 
10 FT Fibroids No 46 26.8 6 Late 
Secretory 
11 FT Fibroids No 47 23.4 2 Early 
Proliferative 
12 FT Menorrhagia No 46 23.1 3 Late 
Proliferative 
13 FT Menorrhagia No 46 27.4 2 Secretory 
14 FT Menorrhagia No 31 24.9 3 Late 
Secretory 
15 FT Prolapse/Fibroid No 47 21.6 2 Proliferative 
16 Pipelle Endometrioma Yes 31 28.3 1 WOI 
17 Pipelle Menorrhagia Yes 31 26.8 2 Secretory 
18 Pipelle  No 38 28.1 3 WOI 
19 Pipelle Menorrhagia No 32 52.2 1 Proliferative 
 
Table 5.3: Patient demographics of samples used to assess multipotency of 
mesodermal lineage 
   
 
0 
 
 
5.2.1: hMSCs are multipotent 
In order to verify that our media promoted differentiation of ASPCs into other cell 
types, hMSCs were cultured and served as a positive control. After two weeks of 
culture in appropriate media, hMSCs were able to differentiate into adipocytes and 
osteoblasts.  
 
5.2.1i: Adipogenesis 
In adipogenic differentiation media, hMSCs began to show changes in appearance 
after only 3 days in culture; cells became round and accumulated lipid vacuoles by 
day 14, which stained positive for Oil Red O. Cells cultured in control media did not 
produce the same morphology (Figure 5.7). mRNA analysis also confirmed 
 mRNA concentration (ng/ l) 260/280 ratio 
A+ A- O+ O- C+ C- A+ A- O+ O- C+ C- 
9 167.6 139.1 1195.1 732.1 655.5 1749.0 1.79 1.69 1.93 1.91 1.94 1.95 
10 131.7 117.7 - - 6.8 119.8 1.69 1.85 - - 1.40 1.78 
11 145.4 158.9 52.6 245.3 75.7 143.9 1.84 1.85 1.93 1.92 1.92 1.77 
12 117.7 172.0 385.5 473.6 517.6 424.2 1.68 1.85 1.90 1.90 1.90 1.90 
13 99.6 267.1 360.8 563.9 438.8 200.0 1.77 1.89 1.82 1.93 1.93 1.76 
14 172.8 277.7 - - 256.4 683.2 1.86 1.87 - - 1.91 1.92 
15 130.0 150.7 - - 133.3 319.4 1.81 1.86 - - 1.85 1.91 
16 62.0 113.6 429.6 512.8 1159.1 658.6 1.68 1.77 1.95 1.95 1.95 1.91 
17 94.3 126.7 191.9 777.4 313.8 475.0 1.83 1.76 1.84 1.89 1.88 1.92 
18 - - 125.0 186.9 173.1 217.4 - - 1.81 1.57 1.62 1.85 
19 - - - - - - - - - - - - 
Table 5.4: mRNA concentration and 260/280 values for samples used to assess 
multipotency of EEp-ASPCs 
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successful differentiation; PPARγ2 and LPL, both early markers of adipogenic 
differentiation, were significantly increased by a mean factor of 29.1 (p=0.02) and 
3468.3 (p=0.0001) respectively, when compared to cells cultured in control 
conditions. Similarly, a more mature marker, aP2 increased by a mean factor of 
18011.9 (p= 0.0001). Although ADiPOQ expression also increased by a factor of 
1332.6, this apparent increase was not found to be statistically significant.  
 
5.2.1i. Osteogenesis 
In osteogenic differentiation media, cells became more spiculated and stained 
positive for ALP after 14 days in culture (Figure 5.8). Again, osteogenic 
differentiation of hMSC was further confirmed by qPCR. Early markers ALP and 
OSX were significantly increased by a mean factor of 5.1 (p=0.001) and 6.9 
(p=0.0001) respectively. Early osteogenic marker Runx2 was increased by a factor of 
1.7, yet this was found to be statistically insignificant. Interestingly, OC was down-
regulated by a mean factor of 0.5 without this apparent decrease in gene expression 
reaching statistical significance.  
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Figure 5.7: hMSCs are capable of adipogenesis 
Microscopic images show hMSCs in adipogenic media at day 1 (a), day 5 (b), day 
10 (c), and Oil Red O staining on day 15 (d). aP2, PPARγ2 and LPL mRNA were 
up-regulated in adipogenic-induced hMSCs (e). Gel electrophoresis of products (f), 
A – adipogenic hMSC, C- control media hMSC.  
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Figure 5.8: hMSCs are capable of osteogenesis. 
Fluorescent images of ALP staining of hMSCs after 14 days in osteogenic (a) 
and control (b) media.  Expression of ALP and OSX were significantly 
increased (c). Gel electrophoresis of products (d), O – osteogenic hMSC, C- 
control media hMSC.  
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5.2.2: EEp-ASPCs are not multipotent 
5.2.2i. Adipogenesis 
Both SSEA-1 enriched and depleted populations began to ‘round up’ after one week 
in adipogenic media, which was not observed in the control. It was also noted that 
cells in adipogenic media became sparser each day. Again, this did not happen in the 
control, suggesting that the ‘rounding up’ is not representative of adipogenic 
differentiation but cell senescence. Consequently, staining with Oil Red O was 
negative with one minor exception (Figure 5.9). An individual cell in the SSEA-1- 
fraction produced small vacuoles. Admittedly, these vacuoles were considerably 
smaller than those observed in induced hMSCs (Figure 5.7). Some tiny Oil Red O 
vacuoles were also present in the control of both fractions. mRNA expression of 
early markers PPARγ2 and LPL in three samples were analysed to confirm findings. 
There was no statistical difference of PPARγ2 expression of SSEA-1+ cells. 
Conversely, in the SSEA-1- fraction, PPARγ2 expression increased by a mean factor 
of 2.6 (p=0.0001). Expression of LPL did not change significantly in either the 
SSEA-1+ or SSEA-1- fraction.  
 
5.2.2ii. Osteogenesis 
Cells in both SSEA-1+ and SSEA-1- populations did not change morphology over 
the period of investigation. However, it also was noted that endometrial epithelial 
cells thrived in the osteogenic media, and this was particularly true for contaminating 
stromal cells. When RNA was quantified, it was also observed that total RNA 
concentrations were considerably higher for cells that had been cultured in the 
osteogenic media (Table 5.4). A very small number of cells stained positively for 
ALP in both the SSEA-1+ and SSEA-1- fractions (Figure 5.10) but this was also 
   
 
5 
similar with cells in control media. qPCR confirmed there was no change in 
expression of osteoblast markers ALP or OSX in the SSEA-1+ fraction. 
Interestingly, in the SSEA-1-population OSX actually decreased in the sample group 
by a mean factor of 0.092 (p=0.0001).  
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Figure 5.2.2i: Endometrial Epithelia are unable to differentiate into adipocytes. SSEA-1– en-
riched populations had a higher degree of stromal contamination (a), see *. Epithelial cells grew in 
small clusters and SSEA-1+ cells depleted in number throughout the time of the experiment (b). 
Once cell in the SSEA-1– fraction produced lipid vacuoles, which stained positive for Oil Red O 
(c), see **. Cells cultured in a 2% Ethanol control produced similar vacuoles (d), **.Gene expres-
sion analysis demonstrated levels of PPARγ2 and LPL remained unchanged in the SSEA-1+ frac-
tion. However, PPARγ2 expression increased in the SSEA-1– population (e).  Gel electrophoresis 
demonstrates products of qPCR (f). 
 
A C+ 
SSEA-1+ SSEA-1- 
A A A A A C C C C C C ntc 
PPARγ2 
LPL 
YWHAZ 
PPARg2 LPL
0.1
1
10
100
SSEA-1+
SSEA-1-
* *p=0.0001
Ex
pr
es
si
on
 R
at
io
f 
Figure 5.9: EEp-ASPCs are unable to undergo adipogenesis 
SSEA-1 depleted populations had a higher degree of stromal contamination (a), see *. 
Epithelial cells grew in small clusters and SSEA-1+ cells d plet d in number throughout 
the tim  of the experiment (b). One ll in the SSEA-1 depleted fraction produced lipid 
vacuoles, which stained positive for Oil Red O (c), see **. Cells cultured in control media 
also produced tiny lipid vacuoles (d), **. Gene expression analysis demonstrated levels of 
PPARγ2 and LPL remained unchanged in the SSEA-1 enriched fraction. However, 
PPARγ2 expression increased in the SSEA-1 depleted population (e). Gel electrophoresis 
demonstrates products of qPCR (f), A- cells in adipogenic medium, C- cells in control 
medium. 
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Figure 5.10: EEp-ASPCs are unable to undergo osteogenesis 
Fluorescent images of ALP staining of SSEA-1 enriched (a) and depleted (b) 
populations after 14 days in osteogenic media.  There was no change in ALP 
expression during the assay, however, OSX was actually down-regulated in the 
SSEA-1- fraction (c). Gel electrophoresis of products (d), O – osteogenic 
induced cells, C- control media hMSC.  
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Figure 5.2.2ii: Endometrial epithelia are unable to differentiate into osteocytes. Both SSEA-1+ 
(a), and SSEA-1– populations (b) had positive ALP staining when compared to respective cells 
cultured in control media (inlet). Gene expression analysis demonstrated levels of ALP and OC 
remained unchanged in the SSEA-1+ fraction whereas OSX was down-regulated in SSEA-1– cells 
that had been cultured in ostegenic media (c).  Gel electrophoresis demonstrates products of qPCR. 
d 
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5.3: Assessment of pluripotency of EEp-ASPCs in vitro 
Three patients were recruited for the study of neurogenic trans-differentiation (for 
demographic data see Table 5.5). SSEA-1+ and SSEA-1- endometrial epithelial cells 
were cultivated in neurogenic media, and analysed with PGP9.5, a mature pan-
neuronal marker after 10 days (Figure 5.11). Cells cultured in epithelial media served 
as a control. Cells in both SSEA-1+ and SSEA-1- fractions became more elongated 
in the neurogenic media. An increased mean percentage of PGP9.5 positive cells 
were observed in cells cultured in the neurogenic media, when compared to those in 
the control; 27.1 ± 6.9% vs.11.4% ± 2.0% respectively (p=0.03). 
 
 
 
 
 
 
 
 
 
 
No. Biopsy  Reason for 
Surgery 
Endometriosis Age BMI Gravida Cycle Stage 
14 FT Menorrhagia No 31 24.9 3 Late Secretory 
20 FT Mittelschmerz No 44 38 4 Early 
Proliferative 
21 FT Fibroids No 44 31.6 3 Early 
Proliferative 
Figure 5.5: Patient demographics for trans-differentiation assay 
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Figure 5.11: Assessment of pluripotency of EEp-ASPCs in vitro 
The percentage of PGP9.5 positive cells increased in SSEA-1 enriched (a) and 
depleted (b) fractions cultured in neurogenic media when compared with 
controls (c). However, this was only significant when the two populations were 
combined (d). 
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Chapter Six: DISCUSSION 
This was an in vitro study exploring the differentiation potential of endometrial 
SSEA-1+ and SSEA-1- epithelial cells. The primary aim was to verify unipotency. 
This required the use of a previously developed 3D culture model to form gland-like 
structures/organoids. A panel of 18 markers was used to analyse the organoids and 
validate their resemblance to in vivo tissue. Differentiation into other lineages was 
also attempted, which encompassed the primary cell culture of SSEA-1+ and SSEA-
1- cells, in media that promoted both mesodermal and ectodermal differentiation.  
 
6.1: SSEA-1+ cells have a greater propensity to differentiate into endometrial 
glands 
Gland-like structures formed within 14 days of 3D culture; consistent with work by 
Fritja et al., in mouse endometrium.206 Organoids demonstrated polarity via the 
presence of apical actin and basal nuclei. Based on immuno-histochemical analysis, 
organoids had positive immuno-reactivity for the hormones implicated in the 
menstrual cycle. Together, these findings suggest the structures formed are 
representative of endometrial glands in vivo, and thus we can validate our 3D model. 
A low number of apoptotic cells and high number of Ki67+ cells supports that our 
model is a suitable environment to study endometrial epithelial behaviour. This is 
coherent with other work, which implies cells behave similarly in a 3D environment 
to how they would in vivo.207 
 
Recently, it was acknowledged that SSEA-1+ cells had a greater propensity to 
produce gland-like structures. Similarly, SPCs from the intestine are capable of 
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reproducing tissue specific structures within a 3D environment.208 Therefore, we 
further support our previous work that SSEA-1 is an EEp-ASPC marker by 
confirming that in vitro tissue reconstitution has been successful. It is likely these 
differentiated structures are a consequence of stem cell activity, as markers of an 
undifferentiated state; NANOG, OCT4a, SOX2 are present in cells in 2D culture but 
lost when transferred to a 3D environment (data not shown).  
 
6.2: Gland-like structures best resemble in vivo glands in PM tissue 
Human endometrium is a dynamic organ that undergoes monthly remodelling 
through differentiation and shedding. Functional glands at the WOI are regarded as 
the most differentiated epithelia; the basalis and PM tissue are thought to harbour the 
SC niche, with germinal glands to produce the transient functionalis. We compared 
gland-like structures, formed in 3D culture, with human endometrial glands in vivo 
(tissue sections), to assess ‘how differentiated’ the 3D structures actually were. 
Polarised organoids were spherical and elliptical in shape; they did not reproduce the 
tortuous and highly coiled structures associated with glands at WOI. In fact, 
structures were very similar in size and morphology to basal and PM glands. 
Furthermore, based upon steroid expression, organoids best resembled PM glands on 
account of low PR expression. These findings could be explained by two theories: 
1. Gland-like structures could be representative of a progenitor population. PM 
and basal glands are thought to harbour the SPC niche: it is this layer of 
endometrium only that is retained during menstruation and the 
menopause.173 The idea is supported by work by Prianishnikov, where PR 
expression is believed to be acquired at terminal differentiation and absent 
on SPCs.124 Although apical actin was present on structures, this was less 
localised than in in vivo tissue, suggesting that gland-like structures are not 
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completely differentiated. In addition, it is interesting that the cells in this 
assay were not sorted on SSEA-1, yet gland-like structures demonstrated 
positive immuno-reactivity for the glycan.  
2. More likely, gland-like structures best resemble PM tissue on account of the 
similar inert hormonal environment. Within pre-menopausal tissue there are 
cyclical changes in oestrogen and progesterone, affecting the morphology 
and function of endometrial cells; oestrogen encourages growth and 
proliferation, whereas progesterone opposes it. It could be considered 
surprising for endometrial gland-like structures to proliferate in an 
environment without oestrogen supplementation. However, our findings 
echo the work of Bukovsky et al., which demonstrated that ovarian epithelia 
are capable of oestrogen dependent oogenesis in vitro without the need of 
exogenous oestrogen.209 Successive work has demonstrated that the culture 
media DMEM/F12 may be concealing a hidden source of oestrogen. 
Phenolsulfanphthalein, the Phenol Red compound, used as a pH indicator in 
most culture medium, contains a lipid impurity, which has a 50% affinity to 
the oestrogen receptor when compared to oestradiol.210 The presence of this 
compound could well explain why organoids have been capable of 
proliferation and partial differentiation in our 3D model. The same 
compound has been found to have a 0.2% potency when compared to 
oestradiol, and this low figure could justify why gland-like structures do not 
resemble the fully differentiated glands seen in human endometrium at WOI, 
when oestrogen is high.210 Out of the in vivo reference groups, PM 
endometrium is exposed to the lowest levels of circulating oestrogen and 
best represents our 3D model.211 Similarly, PM endometrium is also exposed 
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to the lowest levels of progesterone. PR expression levels in organoids were 
most similar to PM tissue. Currently, there is no data to suggest DMEM/F12 
contains any progesterone-like compounds and again supports our findings. 
 
6.3: EEp-ASPCs are unipotent 
Our findings suggest that SSEA-1+ SPCs are unipotent. We have demonstrated that 
SSEA-1+ cells are representative of an SPC population by demonstrating the ability 
of in vitro tissue re-constitution. However, when the same cells were subjected to 
multi-lineage differentiation, the results demonstrated SSEA-1+ cells were unable to 
differentiate into adipocytes and osteoblasts. It is likely that SSEA-1 is representative 
of progenitor TA cells. Naïve SCs are believed to exist in low numbers and the high 
number of SSEA-1+ cells present human endometrium supports TA identity (almost 
all epithelial cells in the basal glands of cycling endometrium and PM tissue 
expressed SSEA-1). In addition, TA cells will divide for a restricted period of time: 
gland-like structures are incapable of surviving after 14 days in culture.212 It is 
possible that a more potent and primitive epithelial ASC exists in human 
endometrium, one that possibly exists in the SSEA-1- fraction.  
 
When looking specifically at the SSEA-1- population; OC, a marker of osteocyte 
differentiation was actually down-regulated. It was noted that osteogenic media 
favoured endometrial proliferation and there was a substantial increase in the number 
of cells. This was probably on account of the reagent vitamin D, which has been 
shown to increase proliferation of endometrial cells in culture.213 The reduction in 
OC expression is likely to be relative to an increase in new endometrial cells. Cells 
cultured in adipogenic media showed marginal increases in PPARγ2 expression and 
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lipid vacuoles were present in one cell. It is unclear whether this cell was epithelial in 
origin. Data from our laboratory (not shown) has demonstrated that the epithelial 
fraction isolated from endometrial tissue has approximately 20% stromal 
contamination. As SSEA-1 is only expressed on epithelial cells, the SSEA-1+ 
fraction is likely to be ‘purer’ than its SSEA-1- counterpart.   The findings of 
differentiation could be due to stroma or resident bone marrow cell contamination, 
both of which we know to be multipotent.138-148,180 A pragmatic approach would be 
to suggest that an EEp-ASPC, irrespective of its place in the SC hierarchy, would be 
unipotent. This is similar to epithelial SPCs found in the skin, liver and 
pancreas.212,214,215 These findings challenge the work of Cervello et al., the authors of 
which claim endometrial epithelia are capable of mesodermal differentiation.141,147 
However, it is worth noting that epithelial cells used by this group were passaged up 
to 15 times: it is possible cellular phenotype changed in culture within this time 
period. Primary human epithelial cells are reputed to be fastidious and difficult to 
grow in culture; after passaging, primary epithelial cultures are often hijacked by 
contaminating stromal cells, which can withstand long term culturing. The study is 
also open to criticism on account of the morphology of differentiated cells. There is 
increasing evidence to suggest lipid vacuoles, which stain positive with Oil Red O, 
can be a response to stress.216 Given the difficulty we experienced at trying to get 
epithelial cells to survive in adipogenic media, and the presence of Oil Red O 
staining in control cells too, we postulate this is the most likely cause of lipid 
vacuoles, rather than differentiation into adipocytes. 
 
The unipotency of endometrial epithelial SPCs may also explain the pathophysiology 
of endometriosis. Current dogma suggests that endometriosis is a consequence of 
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retrograde menstruation of an endometrial SPC.45,217,218 Data from our laboratory 
(not shown) has demonstrated that SSEA-1 expression is significantly greater in the 
functionalis of the endometrium during the secretory phase of women with 
endometriosis. Therefore, it is likely that a greater number of unipotent SSEA-1+ 
cells are thrust into the pelvic cavity via retrograde menstruation. Some lines of 
evidence imply there is an epithelial-mesenchyme relationship governing epithelial 
tissue cell fate. For example, central corneal epithelia can be reprogrammed to form 
pilosebaceous units when transplanted into dermis.99 However, this does not occur in 
endometriosis and further supports the theory that EEp-ASPCs are committed. 
 
A great deal of experimental research has tried to replicate SC niches in order to 
promote SPC differentiation in vitro. When looking specifically at human 
endometrium, perhaps we have been making things too difficult for ourselves. If we 
examine in vivo physiology, we know that human endometrium is in very close 
proximity to the most “pluripotent” niche of all - the developing blastocyst. It is this 
niche, which allows ESC differentiation into all cells types. Since human 
endometrial decidua does not differentiate into other cell types when exposed to the 
blastocyst, it would be irrational to assume it would differentiate into other cell types 
in vitro. 
 
The commitment of endometrial SPCs to produce only endometrium may indeed be 
a design advantage. It is now well recognised that some cells are exchanged at the 
placental border between mother and foetus.219,220 These microchimerisms (Mc) 
usually are foetal-maternal in direction, and have been shown to still be present in 
maternal tissue many years post-partum.221 Conversely, maternal microchimerism 
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(MMc) is the passage of maternal progenitor cells into foetal tissue. This is less well 
researched and currently an area of active investigation. MMc tissue has been found 
in foetal thymus, liver, heart, pancreas and ovary.222 It is postulated MMc occurs to 
promote foetal immunity. However, research remains inconclusive as to whether the 
trafficking of maternal cells in the foetus is beneficial or not. Despite MMcs being 
found in healthy foetal tissue, there is an increased association with disease in the 
progeny, such as Hirschprung’s Disease, biliary atresia, type 1 diabetes, juvenile 
myositis and neonatal lupus.223-227 Most cells transferred are haematopoietic SCs 
(CD34+), which have multipotent properties.222 These findings together suggest the 
transfer of maternal multipotent SPCs into the foetal circulation could be hazardous. 
Therefore, given the close proximity of endometrial decidua to the zygote, it would 
be beneficial for endometrial SPCs to be restricted to unipotency capacity, to prevent 
damage to offspring. 
 
In addition, in 1986, Finn proposed menstruation was the consequence of non-
reversible endometrial differentiation, required to ensure implantation occurred at the 
optimum time.18 Menstruation is a common cause of anaemia in pre-menopausal 
women; it could be regarded as a ‘design flaw’. If Finn were correct, it would seem 
illogical for endometrial SPCs to have the capacity to cross lineages and produce 
other cell types when it cannot ‘de-differentiate’ into early proliferative 
endometrium.  
 
It is also this author’s belief that multipotency of ESt-ASPCs is questionable. 
Although there are numerous papers suggestive of differentiation into adipocytes, 
osteocytes and chondrocytes, the data can be interpreted as misleading; studies are 
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deficient, with experiments lacking basic controls.138-148 Differentiation is a 
transitional process. Therefore, it necessitates parameters to be assessed ‘before’ and 
‘after’ intervention, in this case - culture induction media. As conventional 
measurements, such as PCR and staining, require the fixation or ligation of cells, this 
is not possible in cell culture; the initial measurement would be at the expense of the 
final one. To get around this, stem cell biologists culture the same population of cells 
in induction and non-induction media. At the end of the time period, induction media 
is regarded as the ‘after’ measurement and non-induction is the ‘before’. Therefore, 
to assess differentiation, both before and after measurements are mandatory. 
Unfortunately, current literature regarding the differentiation potential of endometrial 
ASPCs does not volunteer both of these parameters.  Furthermore, as with any 
experiment, a positive control should be included. Although differentiation assays 
require analysis of gene expression and immuno-phenotyping, it is the differentiation 
potential that is really being tested, and therefore MSCs should be the positive 
control; changes in phenotype of studied ASPCs may only be marginal in 
comparison.  
 
6.4: Human endometrium harbours an SPC with neurogenic potential 
Noureddini et al. have demonstrated that cells sorted on CD146+ have the capacity 
to produce neural-like cells when prompted.228 Other work studying endometrial 
stromal cells demonstrated similar effects.151 To the best of our knowledge, this is 
the first study to investigate neural differentiation from endometrial epithelia. 
However, this work is preliminary and further work is required to validate findings. 
Nonetheless, there was an increase in PGP9.5+ cells when cultured in neurogenic 
media, compared with control. Neurons do exist in human endometrium and it would 
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be rational to accept there exists a neural progenitor within the tissue. However, it is 
unlikely SSEA-1+ and SSEA-1- cells trans-differentiated into neural cells, as they 
were unable to demonstrate multipotency in other assays.  PGP9.5 is also a marker of 
neuroendocrine cells and non-small tumour cells in the lung.229 In addition, Quinn et 
al., observed cross reactivity for PGP9.5 with endometrial glands when trying to 
investigate the presence of neural fibres in the endometrium.15 No further details 
were divulged as to the location of the glands or staining pattern, as it was an 
incidental finding. It could be that PGP9.5 is present on endometrial glands 
normally; however it is still interesting that these cells proliferate in the neurogenic 
media, suggesting a neural-like phenotype. Ideally, other neural markers would be 
used along with a comprehensive immuno-histochemical (IHC) study of PGP9.5 in 
tissue sections, but unfortunately this was not possible within the time course of the 
project.   
 
6.5: CK5/6 as a putative SPC for endometriosis 
It was an interesting observation to discover non-gland-like structures in 3D media 
had strong staining intensity for CK5/6. It remains unclear as to what phenotype 
these cells are. An absence of β-catenin and CK18 would suggest stromal 
contamination. These cells would ideally be stained with a specific endometrial 
stromal marker to validate this. At present there appears to be no such thing, as data 
suggest vimentin is present in stroma but also mesodermal derived epithelia.230 
However, if cells were stromal, it is also curious as to why they should express 
CK5/6 in vitro but not in vivo. Similarly, the undefined cells demonstrated negative 
immuno-reactivity for all hormonal receptors, unlike in vivo stromal behaviour. It 
could be that these cells are luminal epithelia, which showed consistent strong 
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staining intensity for CK5/6 in vivo. Conversely, the fact these cells do not form a 
monolayer, resemble in vivo morphology or express hormone receptors, would 
counteract this argument.  
 
It is noteworthy that these cells were only observed in culture samples from an 
endometriosis patient. Due to the small numbers of patients recruited it is difficult to 
elicit whether this is significant, but it does raise suspicion as to whether the cells are 
pathological. One theory may be Epithelial-Mesenchyme Transition (EMT) and 
Mesenchyme-Epithelia Transition (MET). The process of EMT and MET have both 
been implicated in the pathogenesis of endometriosis, and would explain why these 
cells demonstrated negative immuno-reactivity to epithelial markers but this theory 
warrants future work.230  
 
It is possible that these undefined cells are representative of a SC phenotype. In 
breast, the CK5/6+CK18- phenotype has the ability to differentiate into other cells 
types.231,232 We know the endometrium and breast are related; both undergo 
differentiation under the influence of oestrogen.  
 
Perhaps these undefined structures are representative of an endometriosis stem cell. 
Counterarguments would include the negative immuno-reactivity for ER receptors. 
As endometriosis is dependent upon oestrogen it could be assumed an endometriosis 
SPC would have positive ER status. However, ER is believed to be involved in the 
maintenance of ectopic lesions, not necessarily the initiation of disease.  Again, if we 
turn our attention to the breast; a high H-score for CK5/6+ cells in breast carcinoma 
was associated with a higher tumour grade, recurrence, metastasis and low ER 
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immuno-reactivity.232 Together, these findings support the need for further work 
investigating CK5/6 and its role in endometrial physiology and pathology.  
 
6.6: Limitations  
Sample numbers within the study are noticeably small and caused some results to be 
statistically insignificant. Unfortunately, this is a common consequence of primary 
cell culture. Preferably numbers would be higher; it is unknown how this could be 
improved as the study did take place at a tertiary centre for gynaecology, arguably 
the largest women’s specialist hospital in Western Europe. A real obstacle was the 
acquisition of endometriosis samples, as high numbers had to be excluded from the 
study. Patients were recruited at the time of surgery, and subsequently most had 
received hormonal therapy prior to this time. It is also debatable how much the 
‘control’ samples are non-pathological. Patients underwent surgery for menorrhagia, 
benign polyps and pelvic pain. It is possible that these patients may have aberrant 
SPC behaviour that is not representative of physiologic norms. Since completely 
healthy women do not have hysterectomies or undergo investigative procedures, it is 
difficult to access completely healthy endometrium.  
 
IHC analysis of gland-like structures would ideally be scored and compared with in 
vivo tissue. Low numbers of 3D structures meant this was not possible. In addition, it 
is not known whether IHC and antibodies penetrate the organoids in the same way as 
tissue sections; it was noted gland-like structures had greater staining intensity for 
haematoxylin when compared to tissue sections, despite being incubated for the same 
time.  
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When discussing SCs, in theory these should represent a small sub-population of 
cells. Stromal contamination was estimated to be roughly 20%. Because of this, 
combined with suggestions that stromal cells are multipotent, it is difficult to 
establish whether the few cells that have differentiated into other cell types are 
epithelial in origin. A way to overcome this would be to dual sort by FACS on 
CD9+/CD15+. However, from our experience FACs has a significant effect on 
endometrial cell viability and these observations are supported by others.163,164,190 
 
Data for neural differentiation is preliminary; one marker alone has verified results 
via only one assay. Ideally, a panel of neural markers and qPCR would be performed 
against a positive control to establish how ‘successful’ this differentiation is. 
Unfortunately within the course of the project this was not possible. In respect of 
this, there is a huge difficulty within the SC field to establish whether a cell has 
differentiated successfully or whether it has merely adapted to 
advantageous/disadvantageous surroundings. As it stands, most scientists confirm 
successful mesodermal differentiation by one staining method and RT-PCR of two 
markers. However, some lines of evidence suggest these methods are not 
definitive.216 The ultimate test, requires a quantitative in vivo assay to confirm 
‘differentiated’ cells are functional for each cell type, and currently this is not 
available. 
 
6.7: Future Work 
Gland-like structures cultured in 3D media best resemble PM glands on account of 
an inert hormonal environment. We can hypothesise that the introduction of 
exogenous hormones to mimic the menstrual cycle would reproduce the 
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morphological changes associated with cycling endometrial tissue, and this is an area 
of future development. A greater understanding of endometrial stromal cells in 3D 
culture is also warranted, in the hope of developing a 3D co-culture model that 
produces endometrial tissue as a whole. The next step ultimately would be to 
investigate the behaviour of these cells in vivo using an animal model. 
 
The suggestion of a neural pre-cursor in human endometrium raises many questions. 
Eutopic endometrium from endometriosis patients is found to have increased neural 
fibres, and there is a hyper-algesic element to the disease.60 It would be interesting to 
assess if there are differences in endometrial neural progenitor activity in eutopic 
endometrium from endometriosis patients when compared to controls.  
 
Results regarding CK5/6 staining in 3D media are interesting but remain 
inconclusive. There are several theories regarding the presence of these otherwise 
undefined cells and each one of them needs to be explored. The first aim would be to 
reproduce results by increasing patient numbers. Secondly, culture of stromal cells 
and IHC analysis are required to establish whether mesenchyme begin to express 
CK5/6 in a 3D environment and if so, why. Similarly, luminal epithelia should be 
isolated and cultured in the same environment to establish whether these cells are 
responsible for non-defined structures. At present, unlike other mucosal tissue such 
as breast, intestine and skin, there is no marker that discriminates between 
endometrial epithelia. qPCR analysis on CK5/6+ cells verses CK5/6- could be 
implemented to investigate whether there is any increased expression of stem cell 
markers within the positive population. This could also be compared between normal 
and endometriosis samples.  
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Irrespective of stem cells, it is important to note that CK5/6 only stains some and not 
all glandular epithelia in vivo. This warrants the question as to whether there are 
different epithelia sub-types. A full understanding of differentiated endometrial 
epithelia is necessary to appreciate SPC behaviour. Furthermore, the amount of 
research investigating changes in cell behaviour throughout the menstrual cycle and 
between functional and basal layers remains sparse. When one acknowledges the 
endometrium’s regenerative abilities, and the clear distinction between old and new 
tissue, it becomes apparent that this highly dynamic tissue is being overlooked. It 
could be the ideal platform to study stem cell behaviour. 
 
6.8: Conclusion 
There is growing evidence to suggest that the endometrium harbours an ASPC 
population. We have validated our previous work and established that SSEA-1+ cells 
have a greater propensity to produce gland-like structures that resemble glands in PM 
tissue, confirming ASPC status. When the same cells were encouraged to 
differentiate into other cell types from the mesoderm results were disappointing, 
suggesting that SSEA-1+ ASPCs are unipotent. This work agrees with the dogma 
that endometriosis is due to the retrograde menstruation of a unipotent ASPC. 
Interesting, both SSEA-1+ and SSEA-1- cell populations were able to produce an 
increase in neural-like cells when cultured in appropriate induction media. It is 
unclear whether this is trans-differentiation or merely that neurogenic media 
facilitates growth of a neuroendocrine cell phenotype. Nonetheless, it may have 
ramifications in the development of hyper-algesic diseases such as endometriosis. 3D 
culture of eutopic endometriosis endometrium produces non-gland-like structures, 
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which express CK5/6 and may have some implications into the development of the 
disease. A greater understanding of endometrial epithelial composition and 
behaviour throughout the cycle is necessary to appreciate epithelial SPC behaviour. 
Stem cell research is a difficult area of study, as theories and definitions remain 
blurred and divide opinion. It is hoped that this work provides a stepping-stone to 
understanding endometrial epithelial ASPC behaviour in health and disease. 
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STANDARD OPERATING PROCEDURE 
 
Number 04 Version & Issue 1.2 
Title TISSUE PROCESSING 
Author Jo Drury & Lisa Heathcote Date 15/12/2006 
Approved Dr Siobhan Quenby Date 16/12/2006 
Review Date October 2012 Last Reviewed October 2011 
 
BACKGROUND 
Formalin fixed tissue is dehydrated, cleared then impregnated with paraffin wax using the 
automated Shandon Citadel 1000 processing machine. The processing setting for most 
sample types is programme A which operates using the schedule provided below. The 
total processing time is 18 ¾ hours, therefore the processor is generally run overnight. 
Starting the processor at 2pm will result in completion of the cycle at 8:45am the following 
morning. 
 
Programme A Processing Schedule: 
 
4% formalin in neutral buffer 45 minutes 
60% Ethanol 1 hour 
70% Ethanol    1 hour 
90% Ethanol    1 hour 
100% Ethanol    1 hour 
100% Ethanol    1 ½ hours  
100% Ethanol    2 hours 
Xylene 1   1 hour  
Xylene 2   1 ½ hours  
Xylene 3   2 hours  
Wax 1    2 ½ hours  
Wax 2    3 ½ hours 
 
EQUIPMENT  INFORMATION: 
Citadel processor (serial number CA 1390 EO 608) manufacturer: Thermo Electron 
Corporation. Manufacturer’s address: 93 – 96 Chadwick Road, Astmoor, Runcorn, 
Cheshire, WA7 1PR England. 
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MAINTENANCE (CONTRACT AND SERVICING INFORMATION) 
Maintained/serviced by Thermo Fisher Scientific 93 – 96 Chadwick Road, Astmoor, 
Runcorn, Cheshire, WA7 1PR England. Tel: 01928 562 541, Fax: 01928 562 512. 
 
SOLVENT INFORMATION: 
Ethanol and xylene are purchased from Chemistry solvent stores (University of 
Liverpool). The wax (Histoplast PE REF8330) is purchased from Thermo Scientific, 93 – 
96 Chadwick Road, Astmoor, Runcorn, Cheshire, WA7 1PR England.  The 10% neutral 
buffered formalin is purchased from Sigma Life science, Fancy Road, Poole, Dorset, 
BH12 4QH. 
 
HEALTH AND SAFETY PRECAUTIONS: 
Wear a laboratory coat, safety spectacles and nitrile gloves. Xylene and formalin are 
harmful by contact to skin and eyes or if ingested or inhaled. Refer to the risk 
assessments and COSHH forms before starting procedure. 
 
Overnight processing procedures require the completion of permits provided in safety 
circular SCR14/3 (link to document provided below). A ‘Yellow permit’ (for long term 
operation) should be prepared by the DSC or laboratory manager and the copy secured 
in a clear plastic folder on the door outside laboratory 4. The ‘Pink’ permit (valid for the 
duration of the experiment only) should be prepared by the processor user and the 
document should be placed on or adjacent to the apparatus. Information that needs to be 
recorded on the pink copy includes: 
a) experimental details 
b) times and dates of experiment 
c) emergency procedures 
d) name, address and telephone number of the processor user 
e) signature of researcher concerned and a countersignature from the laboratory 
manager/DSC. 
 
PROTOCOL 
A Preparation of Solvent Containers on Processing Machine: 
Between processing runs, ethanol solutions are stored in labelled bottles to prevent 
evaporation. These are found in the metal solvent cabinet under the hood in Laboratory 
4. Therefore, the solvent containers must be re-filled before tissue processing 
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commences. To access the processor solvent container, press the raise button on the 
hand held controller. Remove the evaporation covers from the top of the processor then 
press rotate or check/fill button. The rotate function will cause the operating head 
assembly to advance one position and the check/fill option rotates the head three 
positions. Remove the container using the metal handles and add 1.5L of the required 
ethanol solution (the top of the bevelled edge on the solvent container is approximately 
1.5L). Repeat the process until all ethanol containers are filled. It is also advisable to 
check the level of the xylene, formalin and the wax containers on a regular basis. If fresh 
100% ethanol is used to top up or prepare solutions for the processor ensure the ethanol 
log is updated with the volume used. The ethanol log is situated in DSC office (room 
1128).  
 
B Sample Processing Procedure 
1. Label plastic cassettes with the sample ID number using pencil. 
2. Carefully remove the tissue from the formalin pot using forceps and place into the 
cassette. It is advisable to use small wire inserts if the tissue is in small fragments, 
and a larger yellow cassette if the tissue pieces are substantial. Secure the inserts 
into the plastic cassettes by snapping closed the lid and re-check the sample ID. 
Store the filled cassettes in a Petri dish of formalin until they are all ready to be 
placed into the processor. Dispose of the used formalin in the red labelled waste 
container which is stored below the fume hood. 
2. Arrange the cassettes so they are loosely spaced in the processing baskets. There 
are 3 different sizes of basket – use the smallest one required to contain all the 
cassettes. 
3. Press Go To 1 on the hand held controller, slot the processing baskets onto the 
holder over the formalin and place weight on top of the basket. 
4. Press Lower button on the hand held controller (to lower the basket into the 
formalin). 
5. Check the time is correct by pressing clock (alter time by pressing the + button or 
whilst holding in the clock button if necessary). 
6. Select the appropriate processing time function: 
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Date of 
Processing 
Processing 
Time 
Hand Held Controller Action 
Monday-
Thursday 
Before 2pm Press delay on button 
Monday-
Thursday 
After 2pm Press autostart button 
Friday Before 2pm Press days delay, hold this in, scroll to 2 days using 
the + button then press delay on. 
Friday After 2pm press days delay, hold this in, scroll to 1 day using 
the + button, then press delay on 
 
7. Complete the Citadel 1000 user log (the red folder is situated by the embedding 
station in laboratory 4) with sample, solvent and programme information. 
8. When the processing cycles are completed, switch on the Shandon Histocentre 3 
embedding machine. 
9. Press raise button on the hand held controller and remove baskets from holder. 
Use paper towels to stop wax being dripped onto the floor. 
10. Place blocks into heated reservoir in the embedding machine. 
11. Wipe processing baskets with absorbent towels to remove surplus wax then place 
equipment into the oven (heated to ~100°C) for several minutes to remove any 
residue.  Ensure the rubber seal is removed from the basket holder before it is put 
into the oven. 
12. Soak wire inserts in xylene for several hours/overnight to remove wax residues. 
Leave the inserts in the fume hood to air dry.  
13. Remove the alcohols from the processing machine using the method described in 
section A and pour solutions into the labelled storage bottles using a funnel. The 
storage bottles are then placed back in the flammable solvent metal storage 
cabinets.  
14. Update the Citadel 1000 processing user log.  
 
C Disposal of Waste Solvents 
The solvents must be changed on a regular basis (depending on time of year and 
processor usage) to ensure efficient processing of the tissue samples. Waste solvents 
must be placed in the red solvent waste containers and identified clearly with the 
appropriate labels provided by Lisa Heathcote or Jo Drury. Contaminated waste wax can 
be discarded by pouring the molten solution into a container and cooling until the wax is 
   
 
50 
  
 Standard Operating Procedure 04  
Page 5 of 5 
 
THIS IS A CONTROLLED DOCUMENT.  DO NOT COPY 
 
set. The wax container can then be disposed of in the LWH clinical waste. Refer to the 
waste disposal protocol (SOP 25) for further information. 
 
Other useful SOPs associated with 04 
 
Embedding samples using the Shandon Histocentre 3 machine (SOP 05). 
Processing of endometrial biopsy samples (SOP 03). 
Disposal of solvent waste (SOP 25). 
 
SOP History 
Original SOP prepared by J Drury and L Heathcote in December 2006.  
 
Version 1.1 was prepared to include changes in both Liverpool Women’s Hospital and 
University of Liverpool new logos. In addition, supplier changes for consumables 
information have been updated. 
 
Version 1.2 was prepared to include the latest safety circular information, biopsy insert 
dewaxing procedure and unattended experiment information.  
 
Appendices - Associated Documents 
 
 Document Location 
1 COSHH form for 
processing samples 
COSHH H&S folder 
2 Risk assessment form for 
human samples 
Risk assessment folder 
3 Safety circular on waste 
disposal 
Safety circular folder room 1128 or downloaded from UoL 
safety website . 
4 Unattended experiments 
outside normal working 
hours safety circular 
SCR14/3 
Safety circular folder room 1128 or downloaded from UoL 
safety website 
(http://www.liv.ac.uk/safety/documents_guidance/Safety%
20circulars/Safety_Circular_SCR14.pdf ). 
 
Review Date: October 2012 
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STANDARD OPERATING PROCEDURE 
 
Number 07 Version & Issue 1.2 
Title APES coating procedure 
Author Jo Drury & Lisa 
Heathcote 
Date 21/5/2007 
Approved Dr Siobhan Quenby Date 23/5/2007 
Review Date October 2012 Last Reviewed October 2011 
 
 
BACKGROUND 
The Aminopropyl triethoxy silane (APES) coating procedure is used to improve tissue 
adhesion by producing a positive charge on the surface of the slide. The protocol 
described below was modified from the original method described by Maddox and 
Jenkins in 1991 (full reference provided in the appendices). 
 
HEALTH AND SAFETY REQUIREMENTS 
The APES concentrate is a toxic chemical that is moisture sensitive and requires storage 
at 0-5°C; it is an irritant and can cause burns. Normal laboratory precautions, including 
the wearing of gloves and the use of a fume cupboard, should be taken when handling 
the concentrate solution. Refer to the risk assessments and COSHH forms before starting 
procedure. Place all waste APES solution and ethanol into labelled red solvent waste 
cans and attach a solvent label (available from Lisa Heathcote or Jo Drury by request).  
Disposal of all solvents (ethanol and ethanol/APES mix) is via Solvent Services 
(solvents@liv.ac.uk). 
 
EQUIPMENT INFORMATION: 
• Microscope slides (twin frost size 26 x 76mm-Printed “IVD CE” 90º ground edges, 
catalogue number MAE-1000-03P Pack of 1000) are purchased from Liverpool 
Women’s Hospital (NHS) purchasing department.  
• APES solution (catalogue number A3648) is purchased from Sigma-Aldrich 
Company Ltd. UK distributor address: The Old Brickyard, New Road, Gillingham, 
Dorset, SP8 4XT. 
• Staining racks and glass jars are supplied by Raymond A Lamb Ltd. Manufacturer’s 
address: Units 4 & 5, Parkview industrial estate, Eastbourne, East Sussex, BN23 
6QE England. 
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METHOD: 
Work in the fume hood 
1. Place slides into plastic racks. Each rack holds 24 slides. 
2. Prepare a 2% APES working solution by mixing 5ml APES with 245ml 100% 
ethanol, or for the bulk method 40ml APES with 1960ml 100% ethanol. The APES 
solution is stable for several hours; therefore coat as many racks as possible to 
save reagents and time. 
3. Prepare a glass staining dish containing 100% ethanol. 
Position 1: APES working solution 
Positions 2 – 4: distilled water 
4. Place slide racks in 100% ethanol. Dip several times to dislodge dust etc., and then 
drain the staining racks on absorbent paper towels. 
5. Incubate the slides for 5 minutes in APES working solution.  
6. Rinse slides in three changes of distilled water (2 minutes incubation for each rinse). 
7. Drain slides on absorbent towels and air dry overnight, or dry in a section dryer for a 
few hours at 37°C. 
8. Discard the first change of distilled water. Place the staining dish containing fresh 
distilled water at the last rinse location (position 4). Therefore the second change of 
water has becomes the first etc. 
9. Repeat steps 5 through to 8 for each rack of slides. Allow to dry at room 
temperature or in the drying oven at 37 °C. 
10. Transfer the coated slides to a dust free container labelled ‘APES’ and the date of 
coating (APES slides are stable for approximately 3 months).  
 
BULK METHOD 
 
This is the same method as above, but on a larger scale.  Use large plastic trays to 
contain the APES solution and distilled water.  As this method uses large quantities of 
reagents, it should only be used when time is limited. 
 
Other useful SOPs associated with 07 Procedure 
ImmPress immunohistochemical procedure (SOP 12). 
Cutting paraffin sections (SOP 06) 
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SOP History 
Original SOP prepared by J Drury and L Heathcote in  
This version was prepared to include changes in both Liverpool Women’s Hospital and 
University of Liverpool new logos. 
Version 1.2 was prepared to include the Bulk method and new solvent disposal 
information. 
 
Appendices - Associated Documents 
 Document Location 
1 COSHH assessment for APES coating COSHH assessment folder in the deputy 
departmental safety advisors office 
2 Disposal safety circular Health and safety intranet on the 
University of Liverpool web page 
3. P. H. Maddox and D. Jenkins (1987) 3-
aminopropyltriethoxysilane (APES): a new 
advance in section adhesion J Clin Pathol 
40:1256 - 1260 3 G. Niedobitek and H. 
Herbst (1991). 
Paper copies available from Lisa 
Heathcote by request. 
 
Review Date: October 2012 
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STANDARD OPERATING PROCEDURE 
 
Number 13 Version & Issue 1.1 
Title IMMUNOHISTOCHEMISTRY: HAEMATOXYLIN AND EOSIN 
STAINING OF BIOPSY TISSUE SAMPLES  
Author Jo Drury & Lisa 
Heathcote 
Date 15/12/2006 
Approved Dr Siobhan Quenby Date TBC 
Review Date October 2012 Last Reviewed October 2011 
 
BACKGROUND 
The Haematoxylin and Eosin stain is probably the most widely used stain in 
Histopathology/ Cytopathology. It has the ability to demonstrate an enormous amount of 
tissue structures. The haematoxylin component stains cell nuclei blue / black with good 
intranuclear detail whilst the eosin stains cell cytoplasm and most connective tissue fibres 
in varying shades of pink. 
 
Health and Safety Precautions 
The main health and safety risks to this procedure arise from chemicals/reagents that are 
potentially hazardous, gloves must be worn at all times. Eosin Y aqueous contains 
(formaldehyde: 50 – 00 – 0), causes burns, and may cause sensitisation by skin contact. 
In addition, it is toxic by inhalation, in contact with skin and if swallowed. Haematoxylin 
(Gill 2) contains (ethylene glycol: 107 – 21 – 1; aluminium sulphate 10043 – 01 – 3; acetic 
acid: 64 – 19 – 7). This is harmful if swallowed; very toxic by inhalation; causes severe 
burns, and is irritating to eyes. 
 
METHOD 
Work in a fume hood. Rack slides, bake (see SOP 08 for more details) and use long 
forceps to transfer the rack from dish to dish. Drain off excess liquid from the slide rack on 
paper towels before transfer to the next dish. 
 
For paraffin sections:   
 1.  Dewax prior to staining: 10 min Xylene 1 
   10 min Xylene 2 
   5 min 100% Ethanol 1 
   5 min 100% Ethanol 2 
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   1 min 90% Ethanol  
   1 min 70% Ethanol  
2. 2 min water 
3. Gills 2 Haematoxylin (1 min 30s – 2 min) 
4. Rinse in running tap water until water runs clear 
5. Acid alcohol dip (very briefly) 
6. Blue in running tap water (approximately 5 min) 
7. 70% alcohol 30s – 1 min 
8. 95% alcohol 30s – 1 min 
9.  Eosin Y, aqueous 4 min 
10. Water rinse x 2 
11. Incubate water 2 min 
12. 95% alcohol 20 - 30s 
13. 100% alcohol 1: 30s – 1 min 
14. 100% alcohol 2: 30s – 1 min 
15. Xylene 1: 5mins 
16. Xylene 2: 10mins 
17. DPX and mount 
 
 
Other useful SOPs associated with 13 
Reception and processing of endometrial biopsies (SOP 03). 
Embedding samples using the Shandon Histocentre 3 (SOP 05). 
Cutting paraffin sections (SOP 06) 
Dewaxing paraffin sections for staining (SOP 08) 
Disposal of solvent waste (SOP 25). 
 
 
SOP History 
Original SOP prepared by J Drury and L Heathcote in December 2006.  
This version was prepared to include changes in both Liverpool Women’s Hospital and 
University of Liverpool new logos. 
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Appendices -Associated Documents 
 
 Document Location 
1 Risk and COSHH 
assessments 
Health and Safety folders in the  
departmental safety advisors office 
2   
 
Review Date: October 2012 
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GLAND-LIKE STRUCTURES PM GLANDS 
  +ve Σ % Mean SD +ve Σ % Mean SD 
ER-α 
11 16 68.8% 
88.62% 8.74% 
28 35 80.0% 
81.70% 10.17% 
14 19 73.7% 29 31 93.5% 
15 18 83.3% 44 51 86.3% 
26 33 78.8% 56 68 82.4% 
85 86 98.8% 51 56 91.1% 
23 23 100.0% 14 22 63.6% 
54 57 94.7% 27 31 87.1% 
43 50 86.0% 64 76 84.2% 
45 47 95.7% 36 46 78.3% 
54 57 94.7% 17 27 63.0% 
87 98 88.8% 25 28 89.3% 
29 32 90.6%           
24 27 88.9%           
60 69 87.0%           
76 84 90.5%           
36 39 92.3%           
13 13 100.0%           
38 46 82.6%           
ER-β 
14 15 93.33% 
94.47% 5.55% 
116 116 100.00% 
99.71% 0.93% 
65 67 97.01% 53 53 100.00% 
63 64 98.44% 36 36 100.00% 
41 43 95.35% 35 35 100.00% 
70 76 92.11% 48 48 100.00% 
31 34 91.18% 75 75 100.00% 
28 28 100.00% 66 68 97.06% 
20 20 100.00% 31 31 100.00% 
38 42 90.48% 36 36 100.00% 
13 13 100.00% 18 18 100.00% 
18 18 100.00%           
14 17 82.35%           
36 41 87.80%           
PR 
2 20 10.00% 
31.79% 9.31% 
29 29 100.00% 
83.79% 9.06% 
7 23 30.43% 32 42 76.19% 
6 20 30.00% 22 29 75.86% 
10 28 35.71% 60 63 95.24% 
36 80 45.00% 60 69 86.96% 
18 55 32.73% 76 103 73.79% 
28 75 37.33% 47 54 87.04% 
22 64 34.38% 31 42 73.81% 
22 64 34.38% 66 77 85.71% 
8 46 17.39% 50 60 83.33% 
7 21 33.33%           
6 17 35.29%           
10 48 20.83%           
16 37 43.24%           
7 19 36.84%           
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    +ve Σ  % Mean SD 
14+ 
Neuro+ 
5 13 38.46% 
31.41% 6.44% 
6 19 31.58% 
7 22 31.82% 
3 17 17.65% 
7 22 31.82% 
6 15 40.00% 
5 14 35.71% 
5 16 31.25% 
4 13 30.77% 
6 24 25.00% 
C+ 
3 28 10.71% 
13.26% 3.36% 
3 25 12.00% 
3 22 13.64% 
2 31 6.45% 
5 34 14.71% 
4 27 14.81% 
3 27 11.11% 
4 26 15.38% 
6 32 18.75% 
3 20 15.00% 
14- 
Neuro- 
6 13 46.15% 
33.88% 9.61% 
6 16 37.50% 
3 14 21.43% 
10 36 27.78% 
12 28 42.86% 
12 39 30.77% 
3 11 27.27% 
7 25 28.00% 
10 37 27.03% 
14 28 50.00% 
C- 
2 24 8.33% 
10.76% 3.24% 
3 23 13.04% 
4 28 14.29% 
3 24 12.50% 
2 27 7.41% 
2 20 10.00% 
2 31 6.45% 
4 27 14.81% 
2 28 7.14% 
3 22 13.64% 
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     +ve  Σ  %  Mean  SD 
20+ 
Neuro+ 
14 41 34.15% 
30.69% 9.26% 
9 42 21.43% 
14 42 33.33% 
16 38 42.11% 
13 42 30.95% 
7 30 23.33% 
3 23 13.04% 
7 20 35.00% 
/ /   
9 21 42.86% 
C+ 
4 19 21.05% 
11.54% 5.31% 
2 14 14.29% 
4 22 18.18% 
2 27 7.41% 
2 22 9.09% 
1 27 3.70% 
2 25 8.00% 
2 20 10.00% 
2 14 14.29% 
3 32 9.38% 
20- 
Neuro- 
7 34 20.59% 
24.88% 5.00% 
10 66 15.15% 
10 50 20.00% 
13 55 23.64% 
12 47 25.53% 
15 49 30.61% 
14 51 27.45% 
14 46 30.43% 
13 47 27.66% 
15 54 27.78% 
C- 
4 44 9.09% 
7.50% 3.29% 
3 40 7.50% 
4 32 12.50% 
3 53 5.66% 
4 59 6.78% 
4 40 10.00% 
4 35 11.43% 
2 32 6.25% 
1 31 3.23% 
1 39 2.56% 
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    +ve  	  Σ % Mean SD 
21+ 
Neuro+ 
2 14 14.29% 
19.09% 8.20% 
2 17 11.76% 
4 25 16.00% 
1 15 6.67% 
1 6 16.67% 
3 11 27.27% 
6 19 31.58% 
5 21 23.81% 
2 14 14.29% 
4 14 28.57% 
C+ 
1 22 4.55% 
9.26% 4.39% 
2 19 10.53% 
1 17 5.88% 
1 21 4.76% 
1 16 6.25% 
2 34 5.88% 
3 19 15.79% 
3 24 12.50% 
3 28 10.71% 
3 19 15.79% 
21- 
Neuro- 
9 22 40.91% 
31.20% 6.34% 
5 20 25.00% 
7 22 31.82% 
11 37 29.73% 
8 24 33.33% 
15 42 35.71% 
6 26 23.08% 
8 37 21.62% 
7 21 33.33% 
9 24 37.50% 
C- 
2 27 7.41% 
11.94% 3.32% 
4 48 8.33% 
4 41 9.76% 
5 57 8.77% 
4 25 16.00% 
6 38 15.79% 
5 42 11.90% 
6 37 16.22% 
5 40 12.50% 
6 47 12.77% 
 
 
